

Resonance Health Limited  
Appendix 4E  
Preliminary final report

### 1. Company details

Name of entity:	Resonance Health Limited
ABN:	96 006 762 492
Reporting period:	For the year ended 30 June 2024
Previous period:	For the year ended 30 June 2023

### 2. Results for announcement to the market

	2024 \$	2023 \$	Change \$	Change %
Revenues from ordinary activities	8,589,490	4,404,360	4,185,130	95%
Profit/(Loss) from ordinary activities after tax attributable to the owners of Resonance Health Limited	169,303	(780,361)	949,664	n/a
Profit/(Loss) for the year attributable to the owners of Resonance Health Limited	169,303	(780,361)	949,664	n/a
			2024 Cents	2023 Cents
Basic profit/(loss) per share			0.04	(0.17)
Diluted profit/(loss) per share			0.04	(0.17)

#### Dividends

There were no dividends paid, recommended or declared during the current financial period.

#### Comments

The profit for the Group after providing for income tax amounted to \$169,303 (30 June 2023: \$780,361 loss).

### 3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	0.13	1.57

### 4. Control gained over entities

On 31 May 2024 the Company completed the acquisition of TrialsWest Pty Ltd. The contribution of TrialsWest to the Group's profit from ordinary activities from 1 June 2024 was \$97,869.

### 5. Loss of control over entities

Not applicable.

## 6. Dividends

### *Current period*

There were no dividends paid, recommended or declared during the current financial period.

### *Previous period*

There were no dividends paid, recommended or declared during the previous financial period.

---

## 7. Dividend reinvestment plans

Not applicable.

---

## 8. Details of associates and joint venture entities

Not applicable.

---

## 9. Foreign entities

*Details of origin of accounting standards used in compiling the report:*

Not applicable.

---

## 10. Audit qualification or review

*Details of audit/review dispute or qualification (if any):*

The financial statements have been audited and an unmodified opinion has been issued.

---

## 11. Attachments

*Details of attachments (if any):*

The Annual Report of Resonance Health Limited for the year ended 30 June 2024 is attached.

---

## 12. Signed



Signed

Date: 29 August 2024

Dr Martin Blake  
Chairman  
Perth, Western Australia



**Resonance Health Limited**

**ABN 96 006 762 492**

**Annual Report - 30 June 2024**

For personal use only



Dear Fellow Shareholders,

On behalf of the Board of Directors of Resonance Health Limited (**Resonance Health** or **Company**), it is with great pleasure that I present to you our 2024 Annual Report.

Resonance Health is a leading healthcare technology and services company. The Company's services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials.

Our Company's operational focus is on developing and delivering world class quantitative imaging assessments essential in managing diseases and drug development.

The 2024 financial year was one of significant change for the Company, it saw record analysis volumes for our medical device products, a significant clinical trial contract awarded to our Resonance Clinical business, and the acquisition of TrialsWest, all with a renewed focus on making inroads into the clinical trial ecosystem. These changes along with a strong focus on growth and returns resulted in a record financial result for the Company with revenues up 95% to \$8.6M, and generating net positive operating cashflow of \$1.39M.

The Company also continued its extended proof of concept (**EPoC**) trial for the flagship new product development of non-invasive MRI Liver Fibrosis assessment. The global market for a granular, standardized, non-invasive MRI Liver Fibrosis measurement is significant, particularly in light of the growth in drug development in the metabolic disease space.

I believe our strategy of investing in the 3 businesses that make up Resonance, being the Software as a Medical Device (**SaMD**) business, Resonance Clinical, and Clinical Trial Site Management (**TrialsWest**), has built a strong platform for both organic and acquisitive growth in future periods.

On behalf of the Board, I would like to thank our employees for their efforts and outstanding work during the year. I would also like to thank the patients who used our services and importantly the large group of clinicians and researchers who supported our business.

Yours Sincerely



Dr Martin Blake  
Chairman

For personal use only

Dear Fellow Shareholders,

In last year's letter I outlined a strategy and course of action to deliver shareholder value and a platform for growth in earnings through existing products and customers, expansion of services to clinical trial customers, and sensible accretive acquisitions that add to scale.

We set out to reorganize senior management of the Company, listen to the voice of our customers, and re-focus our efforts on the clinical trials market.

During the period we made a number of strides in this endeavor:

- We appointed a new CFO and VP of Business Development, several engineers, data scientists and scientists to our R&D team, and a number of people left the business
- Our Clinical Research Organisation (**CRO**) business won a \$6.33M 18-month clinical trial management agreement with a major global pharma company
- We made progress on our Extended Proof of Concept to develop a non-invasive MRI liver fibrosis measurement tool
- We generated record revenues of \$8.6M up 95% or \$4.2M from FY23
- The business generated positive operating cash flow of \$1.39M during the period up 985% from FY23 of (\$157k)
- We completed the successful acquisition of the TrialsWest business and opened a new trial site in Aug 2024
- We generated statutory EBITDA of (\$0.1M) and normalized operating EBITDA\* of \$0.7M

On the shoulders of these wonderful results, we expect an even more successful year in FY25 with a full year contribution from TrialsWest, continuing growth in demand for our medical software devices, and the opportunity to bid for further clinical trial management projects.

With a focus on expanding further into the clinical trials ecosystem, and the strong growth opportunities of our 3 business streams we have laid the foundation for shareholder returns in future periods.

I continue to have great confidence in the future of our business and extend my thanks to each of our staff for their contributions to the success of the Company and our performance in FY24. I would also like to thank our shareholders for their faith in the Company.

Yours Sincerely



**Andrew Harrison**  
CEO

*Note: calculated as statutory EBITDA adjusted for share based payments.*

**Resonance Health Limited**

**Contents**

**30 June 2024**

Corporate directory	4
Directors' report	5
Auditor's independence declaration	21
Consolidated statement of profit or loss and other comprehensive income	22
Consolidated statement of financial position	23
Consolidated statement of changes in equity	24
Consolidated statement of cash flows	25
Notes to the consolidated financial statements	26
Consolidated entity disclosure statement	58
Directors' declaration	59
Independent auditor's report to the members of Resonance Health Limited	60
Shareholder information	65

For personal use only

**Resonance Health Limited**  
**Corporate directory**  
**30 June 2024**

Directors

Dr Martin Blake - Non-executive Chairman  
Mr Simon Panton - Non-executive Director  
Dr Travis Baroni - Non-executive Director  
Mr Aaron Brinkworth - Non-executive Director  
Mr Mitchell Wells - Non-executive Director

Chief Executive Officer

Mr Andrew Harrison

Company Secretary

Mr Mitchell Wells

Registered office

Level 1  
141-143 Burswood Road  
BURSWOOD WA 6100  
T: +61 8 9286 5300  
F: +61 8 9286 5399

Principal place of business

Level 1  
141-143 Burswood Road  
BURSWOOD WA 6100  
T: +61 8 9286 5300  
F: +61 8 9286 5399

Share register

Automic Group  
Level 5  
191 St Georges Terrace  
Perth WA 6000  
Telephone: 1300 288 664

Auditor

HLB Mann Judd  
Level 4  
130 Stirling Street  
Perth WA 6000

Solicitors

Steinepreis Paganin  
Level 4  
The Reed Building  
16 Milligan Street  
Perth WA 6000

Bankers

National Australia Bank Limited

Stock exchange listing

Resonance Health Limited shares are listed on the Australian Securities Exchange (ASX) (ASX code: RHT)

Websites

[www.resonancehealth.com](http://www.resonancehealth.com)  
[www.trialswest.com.au](http://www.trialswest.com.au)  
email: [info@resonancehealth.com](mailto:info@resonancehealth.com)

For personal use only

The Directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the **Group** or **Resonance Health**) consisting of Resonance Health Limited (referred to hereafter also as the **Company** or **parent entity**) and the entities it controlled at the end of, or during, the year ended 30 June 2024.

## Directors

The following persons were Directors of Resonance Health Limited during the whole of the financial year and up to the date of this report, unless otherwise stated:

Dr Martin Blake  
Mr Mitchell Wells  
Mr Simon Panton  
Dr Travis Baroni  
Mr Aaron Brinkworth

## Principal activities

The Group's core business includes the development and commercialisation of software-as-medical-device (**SaMD**) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment.

The Group's core SaMD product is FerriScan®, a non-invasive liver analysis technology used for the assessment of iron in the liver. Other Company SaMDs include Cardiac T2\*, for the assessment of iron in the heart, and HepaFat-Scan® for the assessment of fat in and around the liver. The Company also has several AI-assisted SaMDs including FerriSmart®, HepaFat-AI, and LiverSmart®.

In addition to its core business, the Group operates as the Clinical Trial Research Organisation (**CRO**) and local sponsor for a major global pharma company's clinical trial in Australia of a new drug compound. The Group is overseeing aspects of the conduct and delivery of this trial in Australia.

The Group further expanded into the clinical trial ecosystem during the financial year with the acquisition of TrialsWest Pty Ltd (**TrialsWest**). TrialsWest is a clinical research centre that partners with some of the world's leading pharmaceutical and biotechnology companies to help bring new medicines and vaccines to the global community. Specifically, TrialsWest offers site management services to the clinical trial market specializing in the delivery of clinical trials in the community.

## Dividends

There were no dividends paid, recommended or declared during the current or previous financial year.

## Review of operations

The profit for the Group after providing for income tax amounted to \$169,303 (30 June 2023 \$780,361 loss).

Contributing to this result the Group received a \$796k R&D tax incentive refund related to FY23 R&D, in June 2024.

The Group continues to invest in R&D, business development, regulatory and quality affairs, and customer service capabilities to both develop and monetise its technologies and other services globally.

Cash at bank as at 30 June 2024 totalled \$6.85 million, in comparison to the 30 June 2023 cash balance of \$6.36 million. The Group has \$3.17m debt in the form of a secured financing facility, which was used to finance the acquisition of TrialsWest.



### About Resonance Health

Resonance Health Limited is an Australian healthcare technology and services company. The Group's services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development.

Resonance Health's dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (SaMDs) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (AI), include:

- **FerriScan**<sup>®</sup>, a core-lab product that provides an accurate assessment of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart**<sup>®</sup>, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in patients, calibrated against the global gold standard, FerriScan<sup>®</sup>.
- **HepaFatScan**<sup>®</sup>, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
- **HepaFatSmart**<sup>®</sup>, an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liver-fat in patients, for the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart**<sup>®</sup>, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart<sup>®</sup> and HepaFatSmart<sup>®</sup> into a consolidated report providing accurate assessment of LIC and liver fat.
- **CardiacT2\***, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan<sup>®</sup> and CardiacT2\*. CardiacT2\* is TGA and CE Marking regulatory cleared.

The Group has a development pipeline of additional medical imaging analysis products and services, including the **MRI Liver Fibrosis Project**, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis.

### Sales Revenue

Strong demand in diagnostics and clinical trials alongside the commencement of the clinical trial agreement with a major global pharma company resulted in sales revenue for the year of \$8.59 million, a 95% increase on FY2023 of \$4.40 million. This was also reflected in cashflow with total customer receipts for FY24 of \$8.11M, versus total customer receipts for FY23 of \$4.33M, an 87% increase. The major global pharma company agreement contributed approximately \$3.84 million in revenue in the period

Geographically, North America, Asia Pacific and the UK were our biggest markets, with the balance of sales mostly spread across Europe, Asia, and Australia.

### Services

The Group provides its products and services to customers in both diagnostic and clinical trial settings. During the year its products and services were used in over 150 hospitals and MRI centres around the world. Resonance Health's analysis reports are an assessment tool used by clinicians when treating patients with chronic iron-overload and fatty-liver diseases.

Customers in diagnostic settings accounted for less than 33% of revenues, while clinical trial customers accounted for almost 67% of revenues.

Resonance Health continues to actively engage with the global clinical trial market to build on the successful use of its products and services. Due to the highly technical and regulated nature of clinical trial services, revenue from these customers is usually based on multiyear contracts and is higher margin compared to diagnostic customers.

### Summary of Activities

#### *Liver MRI Fibrosis Extended Proof of Concept*

The Group continues to make progress on its extended proof of concept (**EPoC**) for a non-invasive MRI Liver Fibrosis assessment having entered into agreements with two parties during the year to provide critical data for the Group's next phase of testing and research.

The results of the EPoC study, if successful, will allow the Group's continued engagement with pharmaceutical companies developing treatments for chronic liver disease, particularly Non-Alcoholic Fatty Liver Disease (NAFLD), to further assess the commercial potential of the technology. Further, where it is successful, the EPoC study is expected to result in the development of a Liver MRI Fibrosis tool which can start to be used in clinical trials (for investigative use only) whilst the product navigates regulatory clearance in domestic and foreign markets.

International advocacy associations and regulators, including the United States Food & Drug Administration (US FDA) and the LITMUS consortium (Liver Investigation: Testing Marker Utility in Steatohepatitis) in the EU, continue to highlight the urgent need for the development of new, validated, non-invasive biomarkers to assess liver fibrosis to accelerate drug development in NAFLD – the most common cause of chronic liver disease.

#### *Other Product Innovations*

In addition to Liver MRI Fibrosis, Resonance Health continued to invest in the enhancement of its existing products and the development of new products through its broader research and development program during the financial year.

Key product enhancements which continued to be progressed included the validation of a materially shortened MRI imaging protocol for FerriScan<sup>®</sup> and FerriSmart<sup>®</sup> with a targeted 75% reduction in patient MRI scanning time, thereby improving patient experience and increasing scanner throughput.

In addition, significant focus was placed on the ongoing refinement of the machine learning methodology underpinning FerriSmart<sup>®</sup> which is expected to offer benefits to customers using this product as well as potentially opening new markets for the product. It is expected that certain elements of this workstream will also offer potential productivity and cost efficiencies in undertaking FerriScan<sup>®</sup> analysis.

Following the development of HepaFatSmart<sup>®</sup> over recent years, HepaFatScan<sup>®</sup> reporting was enhanced in the financial year to mirror that of HepaFatSmart<sup>®</sup>, and provide a comprehensive, all-in-one multi-metric report that includes; PDFF (Proton Density Fat Fraction), VLFF (Volumetric Liver Fat Fraction), Steatosis Grade and Liver Fat Distribution Map.

Continuing on from the technical and market success of FerriScan<sup>®</sup>'s extension to newer 3 Tesla field strength MRI machines (**3T**) in August 2022, work continued on the development of a 3T version of the Group's Cardiac-T2\* cardiac-iron assessment device with Cardiac 3T now complete and available for use in clinical trials. Validation and documentation work continues to allow this technical development to be ready for regulatory submission in the coming financial year.

#### *Resonance Clinical & Clinical Trials*

The Group continued developing and enhancing its clinical trial capability and revenue expansion strategy during the year, with the Group contracting with a major global pharma company to act as CRO and local Australian sponsor for a clinical trial in Australia of a new drug compound. Under the contract the Group is overseeing aspects of the conduct and delivery of this trial in Australia. This clinical trial agreement is worth an estimated \$6.33 million in revenue to be derived over an ~18-month period and represents a major step forward in the Group's strategy to expand its services in the clinical trial ecosystem. The Group is currently looking at new opportunities to undertake additional clinical trials in Australia.

#### *TrialsWest & Clinical Trials Site Management Services*

The Group further expanded into the clinical trial ecosystem during the financial year with the acquisition of TrialsWest. TrialsWest is a clinical research centre which partners with some of the world's leading pharmaceutical and biotechnology companies to help bring new medicines and vaccines to the global community. Specifically, TrialsWest offers site management services to the clinical trial market specialising in the delivery of clinical trials in the community.

TrialsWest has operated for 12 years, and its founders Dr Helen Pavitt, Michelle Davies, and Prof Peter Bremner are all well respected in the global clinical trials industry. Under the terms of the sale agreement, they will remain in key leadership roles at TrialsWest for at least the next three years. It is expected that TrialsWest will be a source of organic and acquisitive growth going forward as the business looks to expand its presence and actively pursue value accretive acquisitions in this space. In this regard, TrialsWest expanded its geographic footprint shortly after the end of the financial year through opening a new trial site in the north of Perth.

#### *Molecular Medicine*

The Group continues its exciting work on the ASO (antisense oligonucleotide) R&D project which is aimed at the development and validation of a suite of 'cyclophilin-type specific' targeting drug molecules. A number of mouse-based trials have been undertaken with key research partners. The Group is currently planning the next phase of trials focussed on the efficacy of its molecules in both liver and neurological diseases.

#### **Significant changes in the state of affairs**

On 31 May 2024 the Company completed the acquisition of TrialsWest Pty Ltd. Under the terms of the agreement the Company paid \$4 million upfront cash consideration. A further \$4 million may be payable to the TrialsWest vendors pursuant to an earnout arrangement – subject to EBITDA performance targets being achieved during FY24 – FY26. The TrialsWest acquisition was in part funded through a secured debt facility taken out in the period totalling \$3.2 million.

In August 2024, the Group announced the expansion of its TrialsWest business with the upcoming opening of a new trial site in Osborne Park, Western Australia. The addition of this site doubles TrialsWest's physical site and patient capacity and is expected to provide TrialsWest with access to Perth's northern suburbs' patient catchment area.

The Controlled Placement Agreement (CPA) with Acuity Capital expired during the period, with share buy-back of 20,000,000 shares completing on 17 January 2024.

Other than the above, there were no significant changes in the state of affairs of the Group during the financial year.

#### **Matters subsequent to the end of the financial year**

No other matter or circumstance has arisen since 30 June 2024 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

#### **Likely developments and expected results of operations**

Information on likely developments in the operations of the Group and the expected results of operations have not been included in this report because the Directors believe it would be likely to result in unreasonable prejudice to the Group.

## Business risks

The Group is subject to risks of both a general nature and ones that are specific to its business activities including, but not limited to the following:

### *Revenue risks associated with clinical trials*

A significant percentage of the Group's revenue is derived from its technology being used in clinical trials or directly from CRO services such as the clinical trial services agreement entered into with a major global pharma company. This one agreement entered accounted for \$3.8 million in revenue during the year.

Clinical trials are complex and resource intensive. Even if the Group's products and/or services are used successfully in clinical trials, these trials can be cancelled or cut short for any number of reasons. This is of particular importance to the significant revenue expected to be generated by clinical trials as a CRO. The potential risks include:

- lack of effectiveness of any product candidate during clinical trials;
- discovery of serious or unexpected toxicities or side effects experienced by trial participants or other safety issues;
- slower than expected rates of subject recruitment and enrolment rates in clinical trials;
- difficulty in retaining subjects who have been initiated into a clinical trial but may withdraw at any time;
- delays in obtaining regulatory authorisation to commence a trial;
- suspension or termination of a trial by a regulatory agency before or after a trial is commenced; and
- delays or failure in reaching agreement on acceptable terms in clinical trial contracts or protocols with prospective clinical trial sites.

### *Cyber security threat from data breach*

A cyber security breach has the potential to disrupt the Group's information technology platform which is integral to the efficient operation of its business. A serious data breach could expose the Group to statutory liability and reputational damage.

### *Protection of proprietary technology*

The Group's success depends upon it maintaining existing and obtaining new patents along with the protection of its trade secrets. The Group relies upon a combination of patents, trade secret protection (i.e., know how), and confidentiality agreements to protect its intellectual property. The Group may also face competition from companies who develop a substantially similar product to one of its products or proposed products. Many companies have encountered significant problems in protecting and enforcing intellectual property rights in foreign jurisdictions. The Group has certain products whose patents will lapse in the coming years which will expose these products to a higher level of potential competition.

### *Operations in international jurisdictions*

The Group operates in a number of international jurisdictions. The majority of its revenues are generated in the USA, UK, and Europe. Wherever the Group sets up operations it is exposed to a range of multi-jurisdictional risks such as risks relating to difficulty in enforcing contracts, changes to or uncertainty in the relevant legal and regulatory regime (including in relation to taxation and foreign investment and practices of government and regulatory authorities) and other issues in foreign jurisdictions in which the Group operates. Businesses that operate across multiple jurisdictions face additional complexities from the unique business requirements in each jurisdiction.

### *Regulatory and compliance risk*

The Group operates in a complex regulatory environment and in jurisdictions that have varying degrees of enactment and implementation of regulations and are constantly evolving to meet challenges associated with new technology including in relation to privacy and protected health information. The Group's products are registered or have certain regulatory approvals in various jurisdictions including the US FDA, Australian TGA, and European CE. A failure to comply with, or adjust to variations of, regulatory requirements both in Australia and overseas may result in the Company facing regulatory investigation and/or significant claims, and/or being required to adapt or withdraw certain products, which may adversely affect the Group's revenues.

### *Dependence upon key personnel*

The Group depends on the talent and experience of key personnel to deliver on its business strategy. If key personnel leave, it may be difficult to replace them, or to do so in a timely manner or at a comparable expense. Any key personnel who leave to work for a competitor may adversely impact the Group. Additionally, increases in recruitment, wages and contractor costs may adversely impact upon the financial performance of the Group.

### *Reliance on Customers*

Due to the nature of the Company's business, we are dependent on a limited number of key customers for a significant portion of our revenues. A cancellation of a significant order by any of these customers, the loss of any such customers for any reason or the insolvency of any such customers could significantly reduce the Company's ongoing revenue and/or profitability and could materially and adversely affect the Company's financial condition. To manage credit risk and exposure for these key customers, we monitor the level of accounts receivable outstanding to any individual customer at a point in time, as well as performing credit checks on new customers where it is deemed appropriate.

### *Ongoing financing facility*

The group has a significant debt financing facility that is subject to various terms and conditions. There is the risk that this financing facility may not be available in the future or the terms of these facilities could be breached. Any adverse event would have a detrimental impact on the Group's long-term growth and ability to achieve its cashflow forecasts. The group aims to manage its cashflows and finances to comply with the terms of the financing facility and covenants and aims to maintain sufficient liquidity for the business to continue as a going concern. Moreover, the Group regularly engages with its financiers to maintain good relationships.

### *Environmental regulation*

The Group is not subject to any significant environmental regulation under Australian Commonwealth or State law.

### *Information on Directors*

Name:	<b>Dr Martin Blake</b>
Title:	Chair - Non-executive and Independent Appointed 3 October 2007
Qualifications:	MBBS, FRANZCR, FAANMS, MBA, FAICD
Experience and expertise:	Dr Blake is a Radiologist and Nuclear Physician who brings significant technical and industry experience to Resonance Health. He has been a Partner of Perth Radiological Clinic since 1997. Dr Blake has an MBA from Melbourne University, is a Fellow of the Australian Institute of Company Directors, and holds directorships on a number of private Company boards.
Other current listed directorships:	None
Former listed directorships (last 3 years):	None
Special responsibilities:	Chair of the Board of Directors Member of the Remuneration & Nomination Committee Member of the Audit & Risk Committee
Interests in shares:	6,464,677 ordinary shares
Interests in options:	None

**Name:** Mr Mitchell Wells  
**Title:** Director - Non-executive and not Independent, Company Secretary  
 Appointed 28 February 2018, Managing Director from 1 July 2021 to 1 July 2023  
**Qualifications:** L.LB, B.Comm, Dip. Aviation  
**Experience and expertise:** Mr Wells is an experienced senior executive and a qualified lawyer with commercial and legal experience in Australia, the United States of America and the United Kingdom. He has served as a Director and worked as a senior executive of public and private companies including ASX and US Nasdaq listed public companies. He has served as Chair of two large non-profit organisations and has previously served as the Company Secretary of two ASX listed public companies and as the corporate secretary of a US Nasdaq listed public company.

**Other current listed directorships:** None  
**Former listed directorships (last 3 years):** None  
**Special responsibilities:** Director and Company Secretary of Group companies  
**Interests in shares:** 1,610,000 ordinary shares  
**Interest in options:** none  
**Interests in performance rights:** 1,220,000 performance rights with service based vesting conditions.

**Name:** Mr Simon Panton  
**Title:** Director - Non-executive and not Independent  
 Appointed 5 October 2009  
**Qualifications:** None  
**Experience and expertise:** Mr Panton has been a strong supporter of the Company and its technologies over a number of years and is a major shareholder of Resonance Health. Mr Panton brings skills in business and marketing having run his own successful business.

**Other current listed directorships:** None  
**Former listed directorships (last 3 years):** None  
**Special responsibilities:** Member of the Audit & Risk Committee  
 Member of the Remuneration & Nomination Committee  
**Interests in shares:** 74,846,350 ordinary shares  
**Interests in options:** None

**Name:** Dr Travis Baroni  
**Title:** Director - Non-Executive and Independent  
 Appointed 25 November 2016  
**Qualifications:** BSc (Hons), PhD  
**Experience and expertise:** Dr Baroni has broad experience across industrial research, commercialisation of technology, asset valuations and investment banking services. He has a bachelor's degree and PhD in applied physics from The University of Western Australia and managed innovation development and technology strategy in a large company setting as well as being an active investor in early-stage investments. He has worked in investment banking, providing advisory services to equity capital market transactions, corporate research and valuations to clients.

**Other current listed directorships:** None  
**Former listed directorships (last 3 years):** None  
**Special responsibilities:** Chair of the Audit & Risk Committee  
 Member of the Remuneration & Nomination Committee  
**Interests in shares:** 1,130,000 ordinary shares  
**Interests in options:** None

For personal use only

**Resonance Health Limited**  
**Directors' report**  
**30 June 2024**

Name: **Mr Aaron Brinkworth**  
Title: Director - Non-executive and Independent  
Appointed 27 March 2023  
Qualifications: BHlthSc, GAICD  
Experience and expertise: Mr Brinkworth had a 22-year career with Gilead Sciences, Inc. (Nasdaq: GILD) (Gilead) during which time the company grew from a small biotech-pharma company to a multi-billion-dollar global company with annual sales of over USD \$27 billion. He held several commercial, licensing, and patient access roles at Gilead, including that of Executive Director – Global Patient Solutions, where he was responsible for commercial and access strategies for emerging markets. He led Gilead’s commercial and access operations in the Asia Pacific (APAC) where he managed a geographically dispersed team and partners across 31 APAC countries. He completed Gilead’s Senior Leadership Development Program, has a bachelor’s degree in Health Sciences from Edith Cowan University and also serves on a large sized NFP Board for The Royal Lifesaving Society of Western Australia since 2020. He is a graduate of the AICD Company Directors course and maintains active membership of the AICD.

Other current listed directorships: None  
Former listed directorships (last 3 years): None  
Special responsibilities: Chair of Remuneration & Nomination Committee  
Interests in shares: 300,000 ordinary shares  
Interests in options: None

'Other current listed directorships' quoted above are current directorships for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

'Former listed directorships (last 3 years)' quoted above are directorships held in the last 3 years for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

**Company Secretary**

**Mr Mitchell Wells** - L.LB, B.Comm, Dip. Aviation (CPL)  
*Experience:* see above.

**Meetings of Directors**

The number of meetings of the Company's Board of Directors (**Board**) and of each Board committee held during the year ended 30 June 2024, and the number of meetings attended by each Director were:

	Full Board		Remuneration Committee		Audit and Risk Committee	
	Attended	Held	Attended	Held	Attended	Held
Dr M Blake	11	11	2	2	2	2
Mr M Wells	11	11	*	*	*	*
Mr S Panton	11	11	2	2	2	2
Dr T Baroni	11	11	2	2	2	2
Mr A Brinkworth	11	11	2	2	-	-

\* Mr Wells attended Committee meetings in his capacity as Company Secretary of the Company and various Group companies.

Held: represents the number of meetings held during the time the Director held office or was a member of the relevant committee.

For personal use only

## Remuneration report (audited)

The remuneration report details the key management personnel remuneration arrangements for the Group, in accordance with the requirements of the Corporations Act 2001 and its Regulations.

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including all Directors.

The remuneration report is set out under the following main headings:

- Principles used to determine the nature and amount of remuneration
- Details of remuneration
- Service agreements
- Share-based compensation
- Additional information
- Additional disclosures relating to key management personnel

### *Principles used to determine the nature and amount of remuneration*

The objective of the Group's executive reward framework is to ensure reward for performance is competitive and appropriate for the size of the Group and the results delivered. The framework aims to align executive reward with the achievement of operational, strategic and quality objectives and the creation of value for shareholders, and it aims to conform to the market best practice for the delivery of reward.

During the year, the Company engaged specialist remuneration consultants 'The Reward Practice' to conduct an independent third-party review of the Group's remuneration practices consistent with the Board's aspiration of conformance with best remuneration practices. The Chair of the Remuneration & Nomination Committee and the Company Secretary attended several meetings with The Reward Practice during the year and reported to the Board on the progress of the review which, at year end, was continuing.

Among other things the independent remuneration review is looking at the employee incentive program which will be updated and presented to shareholders for approval at the 2024 AGM. Employee long-term equity incentives, most notably performance rights and loan shares, are part of the review. The consultants will also assess and benchmark Director remuneration as part of their review, but this work was not complete at the end of the year.

The Board aims to ensure that executive reward satisfies the following key criteria for good reward governance practices:

- set competitive remuneration packages to attract high calibre employees in the context of the Group's financial capability, prevailing market conditions, particular experience of the individual concerned and the overall performance of the Group; and
- reward employees for retention and performance to better enable long-term growth in shareholder wealth, with the objective of facilitating maximum stakeholder benefit from the retention of a high-quality board and executive team.

The Remuneration & Nomination Committee is responsible for determining and reviewing remuneration arrangements for its directors and executives. The performance of the Group depends on the quality of its directors and executives. The remuneration philosophy is to attract, motivate and retain high performance and high-quality personnel.

The Remuneration & Nomination Committee aims to structure an executive remuneration framework that is market competitive and aligns executive reward to shareholders' interests. The Board consider that it can enhance shareholders' interests by:

- having positive EBITDA and/or economic profit as a component of reward design
- focusing on sustained growth in shareholder wealth, with the aspiration of future dividends, growth in share price, and delivering constant or increasing return on assets as well as focusing the executive on key non-financial drivers of value (e.g. quality and safety)
- attracting and retaining high calibre executives and directors



Additionally, the reward framework seeks to enhance executive loyalty and retention and their interests by:

- rewarding capability and experience and loyalty in tenure with the Group
- reflecting competitive reward for contribution to performance and growth in shareholder wealth
- providing a clear structure for earning rewards

In accordance with best practice corporate governance, the structure of non-executive Director and executive Director remuneration is separate, noting that at present the Company does not have any executive Directors.

#### *Non-executive Director's remuneration*

The Board seeks to set aggregate remuneration at a level that provides the Company with the ability to attract and retain Directors of a high calibre, whilst incurring a cost that is reasonable for the size of the Company and acceptable to shareholders.

Non-executive directors' fees not exceeding an aggregate of \$250,000 per annum have been approved by the Company in a general meeting. The Board is potentially seeking to increase this amount given the growth in the size of the Board in recent years and the growth being experienced by the Group.

The amount of aggregate remuneration sought to be approved by shareholders and the way it is apportioned amongst Directors is reviewed periodically and is currently being reviewed by the independent remuneration consultants engaged by the Group during the year. The Board considers fees paid to non-executive directors of comparable companies when undertaking the review process.

Each of the non-executive Directors receives a fixed fee for their services as directors. There is no direct link between remuneration paid to any of the Directors and corporate performance.

#### *Executive remuneration*

The Group aims to reward executives based on their position, responsibility and tenure, with a level and mix of remuneration that has both fixed and variable components.

The executive remuneration and reward framework has up to four components:

- base pay and non-monetary benefits
- short-term performance incentives
- share-based payments
- other remuneration such as superannuation and long service leave

The combination of these comprises the executive's total remuneration.

Fixed remuneration, consisting of base salary, superannuation and non-monetary benefits, is reviewed annually by the Remuneration & Nomination Committee based on individual and business unit performance, the overall performance of the Group and comparable market remunerations.

Short-term incentives (**STI**) are designed to align the commercial, quality and strategic targets of the Group with the executives' STI award. STI payments may be granted to executives based on specific annual targets and key performance indicators (**KPI's**) being achieved. KPI's may include indicators such as profit contribution, customer satisfaction, leadership and product management.

Long-term incentives (**LTI**) include long service leave and share-based payments including the issue of performance rights and loan shares. The LTI structure for the Group is the subject of particular focus of the third-party independent remuneration review currently being conducted. LTI's are particularly important as they seek to ensure long tenure of skilled and experienced personnel.

All bonuses and incentives are linked to predetermined performance and/or retention criteria. The Board may, however, exercise its discretion in relation to approving incentives and bonuses.

**Resonance Health Limited**  
**Directors' report**  
**30 June 2024**

The Remuneration & Nomination Committee is of the opinion that the improvement in certain financial results such as increased revenue and profitability can be attributed in part to the adoption of performance-based compensation and is satisfied that this improvement will continue to increase shareholder wealth if maintained over the coming years.

*Adoption of Remuneration Report*

The remuneration report for the year ended 30 June 2023 was adopted at the 2023 AGM, with 98.6% of shareholders voting for adoption.

*Details of remuneration*

*Amounts of remuneration*

Details of the remuneration of key management personnel of the Group are set out in the following tables.

The key management personnel of the Group consisted of the following Directors of Resonance Health Limited:

- Dr Martin Blake
- Mr Mitchell Wells
- Mr Simon Panton
- Dr Travis Baroni
- Mr Aaron Brinkworth

And the following persons:

- Mr Andrew Harrison – Chief Executive Officer
- Mr Benjamin Carruthers – Chief Financial Officer

	Short-term benefits			Post-employment benefits	Long-term benefits	Share-based payments	Total
	Cash salary and fees	Cash bonus	Non-Monetary	Super-annuation	Long service leave	Equity-settled	
2024	\$	\$	\$	\$	\$	\$	\$
<i>Non-Executive Directors:</i>							
Dr M Blake	60,000	-	-	6,600	-	-	66,600
Mr S Panton	40,000	-	-	4,400	-	-	44,400
Dr T Baroni	40,000	-	-	4,400	-	-	44,400
Mr A Brinkworth	40,000	-	-	4,400	-	-	44,400
Mr M Wells**	269,093	-	-	6,850	-	46,382	322,325
<i>Other Key Management Personnel:</i>							
Mr A Harrison	342,308	-	9,408	13,173	-	161,129*	526,018
Mr B Carruthers	166,549	-	9,504	17,723	-	111,179*	304,955
	<u>957,950</u>	<u>-</u>	<u>18,912</u>	<u>57,546</u>	<u>-</u>	<u>318,690</u>	<u>1,353,098</u>

\* A Harrison and B Carruthers were issued a combined 3,788,709 performance rights during the year, which were subsequently cancelled on 28 June 2024 prior to meeting any of the vesting conditions. AASB 2 requires the value of any performance rights cancelled to be expensed in full at the time they are cancelled, but no actual benefit was received by either person.

\*\* M Wells transitioned from Managing Director to Non-Executive Director from 1 July 2023 but continues to provide consulting services to the Group.

For personal use only

**Resonance Health Limited**  
**Directors' report**  
**30 June 2024**

	Short-term benefits			Post-employment benefits	Long-term benefits	Share-based payments	Total
	Cash salary and fees	Cash bonus	Non-monetary	Super-annuation	Long service leave	Equity-settled	
2023	\$	\$	\$	\$	\$	\$	\$
<i>Non-Executive Directors:</i>							
Dr M Blake	54,299	-	-	5,701	-	-	60,000
Mr S Panton	36,199	-	-	3,801	-	-	40,000
Dr T Baroni	36,199	-	-	3,801	-	-	40,000
Mr A Brinkworth	10,538	-	-	1,106	-	-	11,644
<i>Executive Directors:</i>							
Mr M Wells	249,412	-	-	25,146	-	48,325	322,883
<i>Other Key Management Personnel:</i>							
Mr N Allan	219,655	-	-	23,064	-	-	242,719
	<u>606,302</u>	<u>-</u>	<u>-</u>	<u>62,619</u>	<u>-</u>	<u>48,325</u>	<u>717,246</u>

The proportion of remuneration linked to performance and the fixed proportion are as follows:

Name	Fixed remuneration		Remuneration linked to performance	
	2024	2023	2024	2023
<i>Non-Executive Directors:</i>				
Dr M Blake	100%	100%	-	-
Mr S Panton	100%	100%	-	-
Dr T Baroni	100%	100%	-	-
Mr A Brinkworth	100%	100%	-	-
<i>Executive Directors:</i>				
Mr M Wells	86%	85%	14%	15%
<i>Other Key Management Personnel:</i>				
Mr A Harrison	69%	n/a	31%	n/a
Mr B Carruthers	64%	n/a	36%	n/a
Mr N Allen	n/a	100%	n/a	-

**Service agreements**

Remuneration and other terms of employment for key management personnel are formalised in service agreements. Details of these agreements are as follows:

Name:	Mr Andrew Harrison
Title:	Chief Executive Officer
Agreement commenced:	1 July 2023
Details:	The employment agreement provides for a salary of \$400,000 plus superannuation and a termination notice of 3 months by the Company or Mr Harrison. In addition, Mr Harrison shall receive annual STIs up to 30% of his base salary subject to KPIs and an annual LTIs up to 30% of his base salary subject to vesting conditions.

**Resonance Health Limited**  
**Directors' report**  
**30 June 2023**

Name: Mr Benjamin Carruthers  
Title: Chief Financial Officer  
Agreement commenced: 9 October 2023  
Details: The employment agreement provides for a salary of \$272,601 plus superannuation and a termination notice of 3 months by the Company or Mr Carruthers. In addition, Mr Carruthers shall receive annual STIs up to 20% of his base salary subject to KPIs and annual LTIs with a value yet to be determined and subject to vesting conditions to be determined.

Key management personnel have no entitlement to termination payments in the event of removal for misconduct.

**Share-based compensation**

*Issue of shares*

Mitchell Wells had 610,000 performance rights vest and convert to shares during the period. Mr Wells served as Managing Director until 30 June 2023, and he continues to provide consulting services to the Group.

Apart from the above, there were no shares issued to Directors and other key management personnel as part of compensation during the year ended 30 June 2024.

*Options*

There were no options over ordinary shares issued to Directors and other key management personnel as part of compensation that were outstanding as at 30 June 2024.

There were no options over ordinary shares granted to or vested by Directors and other key management personnel as part of compensation during the year ended 30 June 2024.

*Performance rights*

There were 5,618,709 performance rights over ordinary shares issued to Directors and other key management personnel during the year ended 30 June 2024.

The terms and conditions of each grant of performance rights over ordinary shares affecting remuneration of Directors and other key management personnel in this financial year or future reporting years are as follows:

Name	Number of rights granted	Valuation date	Vesting date	Fair value per right at grant date
Mitchell Wells	610,000	24 November 2022	1 October 2023	\$0.064
Mitchell Wells	610,000	24 November 2022	1 October 2024	\$0.064
Mitchell Wells	610,000	24 November 2022	1 October 2025	\$0.064
Andrew Harrison	725,806	3 October 2023	1 July 2024	\$0.074
Andrew Harrison	725,806	3 October 2023	1 July 2025	\$0.074
Andrew Harrison	725,806	3 October 2023	1 July 2026	\$0.074
Benjamin Carruthers	537,097	7 September 2023	1 October 2024	\$0.069
Benjamin Carruthers	537,097	7 September 2023	1 October 2025	\$0.069
Benjamin Carruthers	537,097	7 September 2023	1 October 2026	\$0.069

The performance rights issued to Andrew Harrison and Benjamin Carruthers were cancelled prior to vesting on 28 June 2024.

Performance rights granted carry no dividend or voting rights.

For personal use only

**Additional information**

The earnings of the Group for the five years to 30 June 2024 are summarised below:

	2024 \$'000	2023 \$'000	2022 \$'000	2021 \$'000	2020 \$'000
Sales revenue	8,589	4,404	3,828	3,779	3,668
Statutory EBITDA	(129)	(863)	(1,126)	675	653
Normalised EBITDA*	698	(839)	(1,120)	709	993
EBIT	(694)	(1,300)	(1,555)	310	(994)
(Loss)/profit after income tax	169	(780)	(1,142)	586	(715)

\* calculated as statutory EBITDA adjusted for share based payments.

The factors that are considered to affect total shareholders return ('TSR') are summarised below:

	2024	2023	2022	2021	2020
Share price at financial year end (\$)	0.06	0.04	0.06	0.16	0.15
Basic (loss)/earnings per share (cents per share)	0.04	(0.17)	(0.25)	0.14	(0.17)

**Additional disclosures relating to key management personnel**

*Shareholding*

The number of shares in the Company held during the financial year by each Director and other members of key management personnel of the Group, including their personally related parties, is set out below:

	Balance at the start of the year	Conversion of Performance Rights as part of remuneration	Additions	Disposals/ other	Balance at the end of the year
<i>Ordinary shares</i>					
Dr M Blake	6,464,677	-	-	-	6,464,677
Mr M Wells	1,000,000	610,000	-	-	1,610,000
Dr T Baroni	350,000	-	780,000	-	1,130,000
Mr S Panton	74,346,350	-	500,000	-	74,846,350
Mr A Brinkworth	-	-	300,000	-	300,000
Mr A Harrison	-	-	8,000,000	-	8,000,000
Mr B Carruthers	-	-	-	-	-
	82,161,027	610,000	9,580,000	-	92,351,027

For personal use only

*Performance Rights*

The number of performance rights in the Company held during the financial year by each Director and other members of key management personnel of the Group, including their personally related parties, is set out below:

	Balance at the start of		Converted to		Balance at the end of
	the year	Granted	Shares	Cancelled	the year
<i>Performance Rights</i>					
Dr M Blake	-	-	-	-	-
Mr M Wells	-	1,830,000	(610,000)	-	1,220,000
Dr T Baroni	-	-	-	-	-
Mr S Panton	-	-	-	-	-
Mr A Brinkworth	-	-	-	-	-
Mr A Harrison	-	2,177,419	-	(2,177,419)	-
Mr B Carruthers	-	1,611,290	-	(1,611,290)	-
	-	5,618,709	(610,000)	(3,788,709)	1,220,000

*This concludes the remuneration report, which has been audited.*

**Shares under option**

There were no unissued ordinary shares of Resonance Health Limited under option outstanding at the date of this report.

**Shares under performance rights**

There were 12,406,673 unissued ordinary shares of Resonance Health Limited under performance rights outstanding at the date of this report.

**Shares issued on the exercise of options**

There were no ordinary shares of Resonance Health Limited issued on the exercise of options during the year ended 30 June 2024 and up to the date of this report.

**Shares issued on the exercise of performance rights**

There were 5,743,327 ordinary shares of Resonance Health Limited issued on the exercise of performance rights during the year ended 30 June 2024 and up to the date of this report.

**Indemnity and insurance of officers**

The Company has indemnified the Directors and executives of the Company (and other Group companies) for costs incurred, in their capacity as a director or executive, for which they may be held personally liable, except where there is a lack of good faith.

During the financial year, the Company paid a premium in respect of a contract to insure the directors and executives of the Company (and other Group companies) against a liability to the extent permitted by the Corporations Act 2001. The contract of insurance prohibits disclosure of the nature of the liability and the amount of the premium.

**Indemnity and insurance of auditor**

The Company has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the Company or any related entity against a liability incurred by the auditor.

During the financial year, the Company has not paid a premium in respect of a contract to insure the auditor of the Company or any related entity.

For personal use only

### **Proceedings on behalf of the Company**

No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

### **Non-audit services**

Details of the amounts paid or payable to the auditor for non-audit services provided during the financial year by the auditor are outlined in note 25 to the financial statements.

The Directors are satisfied that the provision of non-audit services during the financial year, by the auditor (or by another person or firm on the auditor's behalf), is compatible with the general standard of independence for auditors imposed by the Corporations Act 2001.

The Directors are of the opinion that the services as disclosed in note 25 to the financial statements do not compromise the external auditor's independence requirements of the Corporations Act 2001 for the following reasons:

- all non-audit services have been reviewed and approved to ensure that they do not impact the integrity and objectivity of the auditor; and
- none of the services undermine the general principles relating to auditor independence as set out in APES 110 Code of Ethics for Professional Accountants issued by the Accounting Professional and Ethical Standards Board, including reviewing or auditing the auditor's own work, acting in a management or decision-making capacity for the Company, acting as advocate for the Company or jointly sharing economic risks and rewards.

### **Auditor's independence declaration**

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this Directors' report.

### **Auditor**

HLB Mann Judd continues in office in accordance with section 327 of the Corporations Act 2001.

This report is made in accordance with a resolution of Directors, pursuant to section 298(2)(a) of the Corporations Act 2001.

On behalf of the Directors



---

Dr Martin Blake  
Chair

29 August 2024  
Perth, Western Australia

For personal use only

**AUDITOR'S INDEPENDENCE DECLARATION**

As lead auditor for the audit of the consolidated financial report of Resonance Health Limited for the year ended 30 June 2024, I declare that to the best of my knowledge and belief, there have been no contraventions of:

- a) the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
- b) any applicable code of professional conduct in relation to the audit.

Perth, Western Australia  
29 August 2024



**N G Neill**  
Partner

**hlb.com.au**

**HLB Mann Judd ABN 22 193 232 714**

A Western Australian Partnership

Level 4, 130 Stirling Street, Perth WA 6000 / PO Box 8124 Perth BC WA 6849

**T:** +61 (0)8 9227 7500 **E:** mailbox@hbw.com.au

Liability limited by a scheme approved under Professional Standards Legislation.

HLB Mann Judd is a member of HLB International, the global advisory and accounting network.

For personal use only



**Resonance Health Limited**  
**Consolidated statement of profit or loss and other comprehensive income**  
**For the year ended 30 June 2024**

	Note	2024 \$	2023 \$
<b>Revenue</b>	5	8,589,490	4,404,360
Other income	6	214,194	106,899
<b>Expenses</b>			
Depreciation expense		(242,727)	(136,485)
Amortisation expense		(255,219)	(299,874)
Impairment of research & development		-	(31,460)
Share-based payments		(827,020)	(24,431)
Marketing & travel		(904,644)	(817,667)
Consulting and professional services		(1,702,871)	(236,969)
Employee benefits expense		(3,725,184)	(3,111,198)
Research and development		(835,817)	(708,251)
Statutory and compliance		(227,048)	(197,495)
Foreign exchange gain/(loss)		38,390	285,356
Other expenses		(748,433)	(496,841)
<b>Loss before income tax benefit</b>		(626,889)	(1,264,056)
Income tax benefit	7	796,192	483,695
<b>Profit/(Loss) after income tax benefit for the year attributable to the owners of Resonance Health Limited</b>	21	169,303	(780,361)
Other comprehensive income for the year, net of tax		-	-
<b>Total comprehensive income(loss) for the year attributable to the owners of Resonance Health Limited</b>		<u>169,303</u>	<u>(780,361)</u>
		<b>Cents</b>	<b>Cents</b>
Basic income (loss) per share	34	0.04	(0.17)
Diluted income (loss) per share	34	0.04	(0.17)

*The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes*

Resonance Health Limited  
Consolidated statement of financial position  
As at 30 June 2024

	Note	2024 \$	2023 \$
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents	8	6,854,820	6,361,622
Trade and other receivables	9	2,320,442	1,143,870
Other assets	10	109,980	51,909
Total current assets		<u>9,285,242</u>	<u>7,557,401</u>
<b>Non-current assets</b>			
Property, plant and equipment	11	522,791	385,106
Right-of-use assets	12	492,048	244,494
Intangibles	13	9,863,790	2,713,349
Other assets	10	119,100	82,886
Total non-current assets		<u>10,997,729</u>	<u>3,425,835</u>
<b>Total assets</b>		<u>20,282,968</u>	<u>10,983,236</u>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables	14	1,270,551	732,378
Lease liabilities	15	171,630	100,394
Provisions	16	373,141	31,414
Borrowings	17	320,000	-
Other liabilities	18	11,240	11,188
Deferred Consideration Payable	36	4,000,000	-
Total current liabilities		<u>6,146,562</u>	<u>875,374</u>
<b>Non-current liabilities</b>			
Lease liabilities	15	351,439	172,551
Borrowings	17	2,853,333	-
Total non-current liabilities		<u>3,204,772</u>	<u>172,551</u>
<b>Total liabilities</b>		<u>9,351,334</u>	<u>1,047,925</u>
<b>Net assets</b>		<u>10,931,634</u>	<u>9,935,311</u>
<b>Equity</b>			
Issued capital	19	74,166,888	73,882,788
Reserves	20	2,637,145	2,094,225
Accumulated losses	21	(65,872,399)	(66,041,702)
<b>Total equity</b>		<u>10,931,634</u>	<u>9,935,311</u>

The above consolidated statement of financial position should be read in conjunction with the accompanying notes

Resonance Health Limited  
Consolidated statement of changes in equity  
For the year ended 30 June 2024

	Issued capital \$	Foreign currency translation reserve \$	Share-based payments reserve \$	Accumulated losses \$	Total equity \$
Balance at 1 July 2022	73,882,788	(270,580)	2,340,374	(65,261,341)	10,691,241
Loss after income tax benefit for the year	-	-	-	(780,361)	(780,361)
Other comprehensive income for the year, net of tax	-	-	-	-	-
Total comprehensive income for the year	-	-	-	(780,361)	(780,361)
<i>Transactions with owners in their capacity as owners:</i>					
Share-based payments (note 35)	-	-	24,431	-	24,431
Balance at 30 June 2023	<u>73,882,788</u>	<u>(270,580)</u>	<u>2,364,805</u>	<u>(66,041,702)</u>	<u>9,935,311</u>
	Issued capital \$	Foreign currency translation reserve \$	Share-based payments reserve \$	Accumulated losses \$	Total equity \$
Balance at 1 July 2023	73,882,788	(270,580)	2,364,805	(66,041,702)	9,935,311
Profit after income tax benefit for the year	-	-	-	169,303	169,303
Other comprehensive income for the year, net of tax	-	-	-	-	-
Total comprehensive income for the year	-	-	-	169,303	169,303
<i>Transactions with owners in their capacity as owners:</i>					
Conversion of Performance Rights	284,100	-	(284,100)	-	-
Share-based payments (note 35)	-	-	827,020	-	827,020
Balance at 30 June 2024	<u>74,166,888</u>	<u>(270,580)</u>	<u>2,907,725</u>	<u>(65,872,399)</u>	<u>10,931,634</u>

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes

Resonance Health Limited  
Consolidated statement of cash flows  
For the year ended 30 June 2024

	Note	2024 \$	2023 \$
<b>Cash flows from operating activities</b>			
Receipts from customers		8,110,190	4,334,471
Payments to suppliers and employee		<u>(7,747,755)</u>	<u>(5,476,987)</u>
		362,435	(1,142,516)
Interest received		152,261	25,048
Grants received		76,360	67,000
R&D tax incentive received		<u>796,192</u>	<u>893,440</u>
Net cash provided by/(used in) in operating activities	33	<u>1,387,248</u>	<u>(157,028)</u>
<b>Cash flows from investing activities</b>			
Cash paid to acquire TrialsWest	36	(4,000,000)	-
Cash acquired from acquisition of TrialsWest	36	435,677	-
Payments for property, plant and equipment	11	(229,261)	(288,225)
Payments for intangibles	13	<u>(148,054)</u>	<u>(179,678)</u>
Net cash used in investing activities		<u>(3,941,638)</u>	<u>(467,903)</u>
<b>Cash flows from financing activities</b>			
Proceeds from borrowings		3,200,000	-
Repayment of borrowings		(26,667)	-
Repayment of lease liabilities		(127,922)	(81,967)
Payments for cash backed guarantees		<u>(36,213)</u>	<u>-</u>
Net cash provided by/(used in) in financing activities		<u>3,009,198</u>	<u>(81,967)</u>
Net increase/(decrease) in cash and cash equivalents		454,808	(706,898)
Cash and cash equivalents at the beginning of the financial year		6,361,622	6,783,166
Effects of exchange rate changes on cash and cash equivalents		<u>38,390</u>	<u>285,354</u>
Cash and cash equivalents at the end of the financial year	8	<u><u>6,854,820</u></u>	<u><u>6,361,622</u></u>

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes

## Note 1. General information

The financial statements cover Resonance Health Limited as a Group consisting of Resonance Health Limited and the entities it controlled at the end of, or during, the year. The financial statements are presented in Australian dollars, which is Resonance Health Limited's functional and presentation currency.

Resonance Health Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

Level 1  
141-143 Burswood Road  
BURSWOOD WA 6100  
T: +61 8 9286 5300  
F: +61 8 9286 5399

A description of the nature of the Group's operations and its principal activities are included in the Directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of Directors, on 28 August 2024. The Directors have the power to amend and reissue the financial statements.

## Note 2. Material accounting policies

The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

### New or amended Accounting Standards and Interpretations adopted

The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

AASB 2021-2 Amendments to Australian Accounting Standards – Disclosure of Accounting Policies and Definition of Accounting Estimates makes amendments to various Australian Accounting Standards and AASB Practice Statement 2 Making Materiality Judgements change the way in which accounting policies are disclosed in financial reports. The amendments require disclosure of material accounting policy information rather significant accounting policies and are effective for annual reporting periods beginning on or after 1 January 2023. Accounting policy disclosure has been updated in line with this standard. All other new standards had no material effect.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted and have no material impact.

### Going concern

The financial report has been prepared on the going concern basis, which contemplates continuity of normal business activities and the realisation of assets and settlements of liability in the ordinary course of business.

### Basis of preparation

These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the Corporations Act 2001, as appropriate for for-profit oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB').

#### *Historical cost convention:*

The financial statements have been prepared under the historical cost convention.

## Note 2. Material accounting policies (continued)

### *Critical accounting estimates*

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 3.

### **Parent entity information**

In accordance with the Corporations Act 2001, these financial statements present the results of the Group only. Supplementary information about the parent entity is disclosed in note 30.

### **Business combinations**

Acquisitions of businesses are accounted for using the acquisition method. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition-date fair values of assets transferred by the group, liabilities incurred by the group to the former owners of the acquiree and the equity interest issued by the group in exchange for control of the acquiree. Acquisition-related costs are recognised in profit or loss as incurred.

At the acquisition date, the identifiable assets acquired and the liabilities assumed are recognised at their fair value at the acquisition date, except that:

- Deferred tax assets or liabilities and assets or liabilities related to employee benefit arrangements are recognised and measured in accordance with *AASB 112 Income Taxes* and *AASB 119 Employee Benefits* respectively;
- Liabilities or equity instruments related to share-based payment arrangements of the acquiree or share-based payment arrangements of the group entered into to replace share-based payment arrangements of the acquiree are measured in accordance with *AASB 2 Share-based Payment* at the acquisition date; and
- Assets (or disposal groups) that are classified as held for sale in accordance with *AASB 5 Non-current Assets Held for Sale and Discontinued Operations* are measured in accordance with that Standard.

Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the acquisition-date amounts of the identifiable assets acquired and the liabilities assumed. If, after reassessment, the net of the acquisition-date amounts of the identifiable assets acquired and liabilities assumed exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess is recognised immediately in profit or loss as a bargain purchase gain.

When the consideration transferred by the group in a business combination includes a contingent consideration arrangement, the contingent consideration is measured at its acquisition-date fair value and included as part of the consideration transferred in a business combination. Changes in fair value of the contingent consideration that qualify as measurement period adjustments are adjusted retrospectively, with corresponding adjustments against goodwill. Measurement period adjustments are adjustments that arise from additional information obtained during the 'measurement period' (which cannot exceed one year from the acquisition date) about facts and circumstances that existed at the acquisition date.

The subsequent accounting for changes in the fair value of the contingent consideration that do not qualify as measurement period adjustments depends on how the contingent consideration is classified. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Other contingent consideration is remeasured to fair value at subsequent reporting dates with changes in fair value recognised in profit or loss.

## Note 2. Material accounting policies (continued)

When a business combination is achieved in stages, the group's previously held interests (including joint operations) in the acquired entity are remeasured to its acquisition-date fair value and the resulting gain or loss, if any, is recognised in profit or loss. Amounts arising from interests in the acquiree prior to the acquisition date that have previously been recognised in other comprehensive income are reclassified to profit or loss, where such treatment would be appropriate if that interest were disposed of.

If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the group reports provisional amounts for the items for which the accounting is incomplete. Those provisional amounts are adjusted during the measurement period (see above), or additional assets or liabilities are recognised, to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the amounts recognised as of that date.

### Principles of consolidation

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Resonance Health Limited ('Company' or 'parent entity') as at 30 June 2024 and the results of all subsidiaries for the year then ended. Resonance Health Limited and its subsidiaries together are referred to in these financial statements as the 'Group'.

Subsidiaries are all those entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are de-consolidated from the date that control ceases.

Intercompany transactions, balances and unrealised gains on transactions between entities in the Group are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.

The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference between the consideration transferred and the book value of the share of the non-controlling interest acquired is recognised directly in equity attributable to the parent.

Where the Group loses control over a subsidiary, it derecognises the assets including goodwill, liabilities and non-controlling interest in the subsidiary together with any cumulative translation differences recognised in equity. The Group recognises the fair value of the consideration received and the fair value of any investment retained together with any gain or loss in profit or loss.

### Operating segments

Operating segments are presented using the 'management approach', where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers ('CODM'). The CODM is responsible for the allocation of resources to operating segments and assessing their performance. The Board of Directors have been identified as the CODM.

### Revenue recognition

Refer to note 5 for accounting policy.

### Government grants

Grants from the government are recognised at their fair value where there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions.

## Note 2. Material accounting policies (continued)

### *Interest*

Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

### *Other revenue*

Other revenue is recognised when it is received or when the right to receive payment is established.

### **Income tax**

Resonance Health Limited (the 'head entity') and its wholly-owned Australian subsidiaries have formed an income tax consolidated group under the tax consolidation regime. The head entity and each subsidiary in the tax consolidated group continue to account for their own current and deferred tax amounts. The tax consolidated group has applied the 'separate taxpayer within group' approach in determining the appropriate amount of taxes to allocate to members of the tax consolidated group.

### **Trade and other receivables**

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any allowance for expected credit losses. Trade receivables are generally due for settlement within 90 days.

The Group has applied the simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue.

Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

### **Property, plant and equipment**

Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Depreciation is calculated on a straight-line basis to write off the net cost of each item of property, plant and equipment (excluding land) over their expected useful lives as follows:

Plant and equipment	3-5 years
---------------------	-----------

The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date.

Leasehold improvements are depreciated over the unexpired period of the lease or the estimated useful life of the assets, whichever is shorter.

An item of property, plant and equipment is derecognised upon disposal or when there is no future economic benefit to the Group. Gains and losses between the carrying amount and the disposal proceeds are taken to profit or loss.

### **Intangible assets**

#### *Research and development*

Expenditure on research activities is recognised as an expense in the period in which it is incurred. Where no internally-generated intangible asset can be recognised, development expenditure is recognised as an expense in the period as incurred.



## Note 2. Material accounting policies (continued)

An intangible asset arising from development expenditure on an internal project is recognised if, and only if, all of the following have been demonstrated:

- The technical feasibility of completing the intangible asset so that it will be available for use or sale;
- The intention to complete the intangible asset and use or sell it;
- The ability to use or sell the intangible asset;
- How the intangible asset will generate probably future economic benefits;
- The availability of adequate technical, financial and other resources to complete development and to use or sell the intangible asset; and
- The ability to measure reliably the expenditure attributable to the intangible asset during its development.

The amount initially recognised for internally generated intangible assets is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above.

Subsequent to initial recognition, internally-generated intangible assets are reported at cost less accumulated amortisation and accumulated impairment losses, on the same basis as intangible assets acquired separately.

The useful life used in the calculation of amortisation is 10 years.

### Goodwill

Goodwill is initially recognised and measured as set out in the business combinations policy above.

Goodwill is not amortised but is reviewed for impairment at least annually. For the purpose of impairment testing, goodwill is allocated to each of the group's cash-generating units (or groups of cash-generating units) expected to benefit from the synergies of the combination. Cash-generating units to which goodwill has been allocated are tested for impairment annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit. An impairment loss recognised for goodwill is not reversed in a subsequent period.

On disposal of a cash-generating unit, the attributable amount of goodwill is included in the determination of the profit or loss on disposal.

### Borrowings

Loans and borrowings are initially recognised at the fair value of the consideration received, net of transaction costs. They are subsequently measured at amortised cost using the effective interest method.

### Fair value measurement

When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market.

Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interests. For non-financial assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

## Note 2. Material accounting policies (continued)

### New Accounting Standards and Interpretations not yet mandatory or early adopted

Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the Group for the annual reporting period ended 30 June 2024. The Group has not yet assessed the impact of these new or amended Accounting Standards and Interpretations.

## Note 3. Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

### *Impairment of intangibles*

The Group determines whether intangibles with indefinite useful lives are impaired at least on an annual basis. This requires an estimation of the recoverable amount of the cash generating units to which the intangibles with indefinite useful lives are allocated. The assumptions used in this estimation of recoverable amount and the carrying amount of intangibles with indefinite useful lives are discussed in note 13.

Additionally, the Group assesses impairment at the end of each reporting period by evaluating conditions and events specific to the Group that may indicate impairment triggers. Recoverable amounts of relevant assets are reassessed using value-in-use calculations which incorporate various key assumptions.

With respect to cash flow projections growth rates have been factored into valuation models for the next five years on the basis of management's expectations regarding the Group's continued ability to increase market share based on contractual obligations already in place and historical sales growth rates.

Historic Group averages have been used to reflect projected cash flow growth rates in year 1 and year 2. In subsequent periods a consistent growth rate has been attached as a conservative estimate for use in the impairment calculation.

### *Share-based payment transactions*

The Group measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using the Black-Scholes model taking into account the terms and conditions upon which the instruments were granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity.

### *Estimation of useful lives of assets*

The Group determines the estimated useful lives and related depreciation and amortisation charges for its property, plant and equipment and finite life intangible assets. The useful lives could change significantly as a result of technical innovations or some other event. The depreciation and amortisation charge will increase where the useful lives are less than previously estimated lives, or technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down.

### *Impairment of non-financial assets other than goodwill and other indefinite life intangible assets*

The Group assesses impairment of non-financial assets other than goodwill and other indefinite life intangible assets at each reporting date by evaluating conditions specific to the Group and to the particular asset that may lead to impairment. If an impairment trigger exists, the recoverable amount of the asset is determined. This involves fair value less costs of disposal or value-in-use calculations, which incorporate a number of key estimates and assumptions.

**Note 3. Critical accounting judgements, estimates and assumptions (continued)**

*Lease term*

The lease term is a significant component in the measurement of both the right-of-use asset and lease liability. Judgement is exercised in determining whether there is reasonable certainty that an option to extend the lease or purchase the underlying asset will be exercised, or an option to terminate the lease will not be exercised, when ascertaining the periods to be included in the lease term. In determining the lease term, all facts and circumstances that create an economical incentive to exercise an extension option, or not to exercise a termination option, are considered at the lease commencement date. Factors considered may include the importance of the asset to the Group's operations; comparison of terms and conditions to prevailing market rates; incurrence of significant penalties; existence of significant leasehold improvements; and the costs and disruption to replace the asset. The Group reassesses whether it is reasonably certain to exercise an extension option, or not exercise a termination option, if there is a significant event or significant change in circumstances.

**Note 4. Operating segments**

*Identification of reportable operating segments*

The chief operating decision maker is considered to be the Company's Board of Directors. The Group's operating segments are determined by differences in the type of activities performed. The financial results of the Group's operating segments are reviewed by the Board of Directors on a quarterly basis.

*Business Segments*

The following table presents revenue and profit/(loss) information and certain asset and liability information regarding business segments for the year ended 30 June 2024.

	Services	Research and development	Corporate	CRO	TrialsWest	Total
2024	\$	\$	\$	\$	\$	\$
<b>Revenue</b>						
Sales to external customers	4,540,921	-	-	3,843,815	204,754	8,589,490
<b>Total revenue</b>	4,540,921	-	-	3,843,815	204,754	8,589,490
Total revenue	4,540,921	-	-	3,843,815	204,754	8,589,490
Other expenses	(1,118,134)	(1,091,036)	(5,648,800)	(1,465,718)	(106,885)	(9,430,573)
Other income	-	-	214,194	-	-	214,194
<b>(Loss)/profit before income tax benefit</b>	3,422,787	(1,091,036)	(5,434,606)	2,378,097	97,869	(626,889)
Income tax benefit						796,192
<b>Loss after income tax benefit</b>						169,303
<b>Assets</b>						
Segment assets	1,133,273	2,606,183	8,109,366	619,803	7,814,343	20,282,968
<b>Total assets</b>						20,282,968
<b>Liabilities</b>						
Segment liabilities	1,180,876	22,964	2,958,393	626,189	4,562,914	9,351,334
<b>Total liabilities</b>						9,351,334

Note 4. Operating segments (continued)

2023	Services \$	Research and development \$	Corporate \$	CRO \$	TrialsWest \$	Total \$
<b>Revenue</b>						
Sales to external customers	4,404,360	-	-	-	-	4,404,360
<b>Total revenue</b>	<b>4,404,360</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>4,404,360</b>
Total revenue	4,404,360	-	-	-	-	4,404,360
Other expenses	(993,898)	(1,039,585)	(3,741,832)	-	-	(5,775,315)
Other income	-	-	106,899	-	-	106,899
<b>(Loss)/profit before income tax benefit</b>	<b>3,410,462</b>	<b>(1,039,585)</b>	<b>(3,634,933)</b>	<b>-</b>	<b>-</b>	<b>(1,264,056)</b>
Income tax benefit						483,695
<b>Loss after income tax benefit</b>						<b>(780,361)</b>
<b>Assets</b>						
Segment assets	1,104,333	2,713,349	7,165,554	-	-	10,983,236
<b>Total assets</b>						<b>10,983,236</b>
<b>Liabilities</b>						
Segment liabilities	-	-	1,047,925	-	-	1,047,925
<b>Total liabilities</b>						<b>1,047,925</b>

*Geographical Segments*

The company earns revenue in three significant geographical regions, countries are grouped in the regions of Asia/Pacific, North America and Europe-Middle-East-Africa (EMEA).

All non-current assets are located in Australia being the Asia/Pacific region, applicable disclosure information is disclosed in Business Segment assets and no additional disclosure is made.

	2024 \$	2023 \$
Asia/Pacific	4,318,677	293,885
North America	2,635,543	2,779,833
EMEA	1,635,270	1,330,642
Total sales to external customers	<u>8,589,490</u>	<u>4,404,360</u>

The group derived 45% of its revenue from one customer during the 2024 FY.

## Note 5. Revenue

### *Accounting policy for revenue*

The Group generates revenue largely in the North America, Asia Pacific and Europe-Middle-East-Africa (EMEA) regions.

The revenue and profits recognised in any period are based on the delivery of performance obligations and an assessment of when control is transferred to the customer.

In determining the amount of revenue and profits to record, and related statement items (such as contract fulfilment assets, capitalisation of costs to obtain a contract, trade receivables, accrued income and deferred income) to recognise in the period, management is required to form a number of key judgements and assumptions. This includes an assessment of the costs the Group incurs to deliver the contractual commitments and whether such costs should be expensed as incurred or capitalised.

Revenue is recognised either when the performance obligation in the contract has been performed (so 'point in time' recognition) or 'over time' as control of the performance obligation is transferred to the customer.

For contracts with multiple components to be delivered such as establishment services, trial establishment project and data management, project and data management services and analysis services management applies judgement to consider whether those promised goods and services are (i) distinct - to be accounted for as separate performance obligations; (ii) not distinct - to be combined with other promised goods or services until a bundle is identified that is distinct or (iii) part of a series of distinct goods and services that are substantially the same and have the same pattern of transfer to the customer.

At contract inception the total transaction price is estimated, being the amount to which the Group expects to be entitled and has rights to under the present contract.

The transaction price does not include estimates of consideration resulting from changed orders for additional goods and services unless these are agreed.

Once the total transaction price is determined, the Group allocates this to the identified performance obligations in proportion to their relative stand-alone selling prices and recognises revenue when (or as) those performance obligations are satisfied.

For each performance obligation, the Group determines if revenue will be recognised over time or at a point in time. Where the Group recognises revenue over time for long term contracts, this is in general due to the Group performing and the customer simultaneously receiving and consuming the benefits provided over the life of the contract.

For each performance obligation to be recognised over time, the Group applies a revenue recognition method that faithfully depicts the Group's performance in transferring control of the goods or services to the customer. This decision requires assessment of the real nature of the goods or services that the Group has promised to transfer to the customer. The Group applies the relevant output or input method consistently to similar performance obligations in other contracts.

When using the output method the Group recognises revenue on the basis of direct measurements of the value to the customer of the goods and services transferred to date relative to the remaining goods and services under the contract. Where the output method is used, in particular for long term service contracts where the series guidance is applied, the Group often uses a method of time elapsed which requires minimal estimation. Certain long term contracts use output methods based upon estimation of number of users, level of service activity or fees collected.

When using the input method the Group recognises revenue on the basis of the entity's costs incurred to the satisfaction of a performance obligation relative to the total expected cost budget for that contract.

If performance obligations in a contract do not meet the over time criteria, the Group recognises revenue at a point in time. This may be at the point of physical delivery of goods and acceptance by a customer or when the customer obtains control of an asset or service in a contract with customer-specified acceptance criteria.

#### Note 5. Revenue (Continued)

The Group disaggregates revenue from contracts with customers by contract type, which includes (i) commercial revenue, (ii) voucher revenue, (iii) clinical trial revenue and (iv) other study income as management believe this best depicts how the nature, amount, timing and uncertainty of the Group's revenue and cash flows.

The nature of contracts or performance obligations categorised within this revenue type includes (i) establishment services, (ii) trial establishment project and data management, (iii) project and data management services, and (iv) analysis services.

The service contracts in this category include contracts with either a single or multiple performance obligations.

The Group considers that the services provided meet the definition of a series of distinct goods and services as they are (i) substantially the same and (ii) have the same pattern of transfer (as the series constitutes services provided in distinct time increments (e.g. monthly or annual services)) and therefore treats the series as one performance obligation.

##### (i) Establishment services

Encompasses different services from which the customer is able to benefit from on their own or with other readily available resources. Accordingly, revenues are recognised at a point in time when the service is delivered.

##### (ii) Trial establishment project and data management

Point in time revenues are recognised when the contract is signed and the trial establishment activities have been performed. The customer can benefit from these activities on their own or with other readily available resources.

Over time revenues are recognised on the basis of the entity's costs incurred to the satisfaction of a performance obligation relative to the total expected cost budget for that contract.

##### (iii) Project and data management services

Revenues are recognised over the contract period as the service is provided.

##### (iv) Analysis services

Revenues are recognised at a point in time following the completion of the analysis and report compilation.

#### Contract fulfilment assets and liabilities

As a result of the contracts which the Group enters into with its customers, a number of different assets and liabilities are recognised on the Group's Statement of Financial Position. These include but are not limited to:

- Trade receivables
- Accrued income
- Deferred income

**Note 5. Revenue (Continued)**

Deferred and accrued income

The Group's customer contracts include a diverse range of payment schedules dependent upon the nature and type of goods and services being provided. The Group often agrees payment schedules at the inception of long term contracts under which it receives payments throughout the term of the contracts. These payment schedules may include performance-based payments or progress payments as well as regular monthly payments for ongoing service delivery. Payments for transactional goods and services may be at delivery date, in arrears or part payment in advance.

Where payments made are greater than the revenue recognised at the period end date, the Group recognises a deferred income contract liability for this difference. Where payments made are less than the revenue recognised at the period end date, the Group recognises an accrued income contract asset for this difference.

Disaggregation of revenue

The group derives its revenue from the services at a point in time and over time in the following major categories. This is consistent with the revenue information that is disclosed for each reportable segment:

	2024 \$	2023 \$
<i>Revenue from contracts with customers</i>		
<u>At a point in time:</u>		
Commercial revenue	2,817,576	2,520,745
Clinical trials	744,958	607,748
Other studies	351,762	345,416
<u>Over time:</u>		
Clinical trials	4,675,194	930,451
Revenue	<u>8,589,490</u>	<u>4,404,360</u>

*Reconciliation of revenue from contracts with customers with the amounts disclosed in segment information*

	2024 \$	2023 \$
Segment revenue	8,589,490	4,404,360
Adjustments and eliminations	-	-
Total revenue from contracts with customers	<u>8,589,490</u>	<u>4,404,360</u>

**Note 6. Other income**

	2024 \$	2023 \$
Subsidies and grants	76,360	67,000
Interest revenue	137,834	39,899
Total other income	<u>214,194</u>	<u>106,899</u>

For personal use only

Note 7. Income tax

	2024	2023
	\$	\$
<i>Income tax benefit</i>		
Research and Development tax offset	<u>(796,192)</u>	<u>(483,695)</u>
Aggregate income tax benefit	<u>(796,192)</u>	<u>(483,695)</u>
<i>Numerical reconciliation of income tax benefit and tax at the statutory rate</i>		
Loss before income tax benefit	<u>(626,889)</u>	<u>(1,264,056)</u>
Tax at the statutory tax rate of 25%	(156,722)	(316,014)
Tax effect amounts which are not deductible/(taxable) in calculating taxable income:		
Expenses that are not deductible in determining taxable profit	659,286	103,513
Non-assessable income	<u>-</u>	<u>(5,974)</u>
	659,286	(218,475)
Unused tax losses not recognised as deferred tax assets	-	171,179
Recognition of previously unrecognised tax losses	(355,875)	-
Effect of temporary differences not recognised in deferred tax assets and liabilities	229,299	47,296
Research and Development tax offset	<u>(1,172,179)</u>	<u>(483,695)</u>
Income tax benefit	<u>(796,192)</u>	<u>(483,695)</u>

**Unrecognised deferred tax balances**

	2024	2023
	\$	\$
<i>Deferred tax assets not recognised</i>		
Deferred tax assets not recognised comprises temporary differences attributable to:		
Losses available for offset against future taxable income - revenue	1,418,940	2,304,481
Amortisation and depreciation timing differences	140,368	140,368
Business related costs	-	543
Accrued expenses and liabilities	275,272	131,525
Others	<u>7,398</u>	<u>7,113</u>
Total deferred tax assets not recognised	<u>1,841,977</u>	<u>2,584,030</u>

The above potential tax benefit, which excludes tax losses, for deductible temporary differences has not been recognised in the statement of financial position as the recovery of this benefit is uncertain. Tax losses may be carried forward indefinitely under current tax legislation provided conditions for deductibility are met.

For personal use only



**Note 7. Income tax (continued)**

	2024 \$	2023 \$
<i>Deferred tax liabilities not recognised</i>		
Deferred tax liabilities not recognised comprises temporary difference attributable to:		
Capitalised research and development costs	651,546	678,337
Accrued income	-	3,964
Unrealised foreign exchange gains	6,368	62,172
	<u>657,914</u>	<u>744,473</u>

Deferred tax liabilities have not been recognised in respect of these taxable temporary differences as the entity is able to control the timing of the reversal of the temporary differences and it is probable that the temporary differences will not reverse in the foreseeable future.

**Tax Consolidation**

Resonance Health Limited and its 100% owned Australian resident subsidiaries implemented the tax consolidation legislation from 1<sup>st</sup> July 2012.

**Note 8. Cash and cash equivalents**

	2024 \$	2023 \$
<i>Current assets</i>		
Cash at bank	3,404,398	5,324,561
Term deposits	3,450,422	1,037,061
	<u>6,854,820</u>	<u>6,361,622</u>

Cash at bank earns interest at floating rates based on daily bank deposit rates.

Term deposits are made for varying periods depending on the immediate cash requirements of the Group and earn interest at the respective term deposit rates.

**Note 9. Trade and other receivables**

	2024 \$	2023 \$
<i>Current assets</i>		
Trade receivables	2,350,677	1,104,333
Expected credit loss	(40,865)	-
Other receivables	10,630	39,537
	<u>2,320,442</u>	<u>1,143,870</u>

Trade receivables are non-interest bearing and are generally on terms of 14 days to 90 days. All amounts are short term. The carrying value of trade receivables is considered a reasonable approximation of fair value.

**Note 9. Trade and other receivables (continued)**

*Allowance for expected credit losses*

The ageing of the receivables and allowance for expected credit losses provided for above are as follows:

	<b>Carrying amount</b>	
	<b>2024</b>	<b>2023</b>
	\$	\$
Not overdue	1,847,343	586,325
30 - 60 days overdue	30,186	64,410
60 - 90 days overdue	44,226	65,437
90 - 120 days overdue	53,899	37,075
>120 days overdue	344,787	390,623
	<u>2,320,441</u>	<u>1,143,870</u>

The Group applies the AASB 9 simplified model of recognising lifetime expected credit losses for all trade receivables as these items do not have a significant financing component.

In measuring the expected credit losses, the trade receivables have been assessed on a collective basis as they possess shared credit risk characteristics.

Trade receivables are written off when there is no reasonable expectation of recovery. The Group is actively working with customers in relation to payments of outstanding receivable balances with systems and processes set up to enable collection of funds.

On the basis determined above, the expected credit loss for trade receivables as at 30 June 2024 was determined as \$40,865 (30 June 2023: \$nil).

**Note 10. Other assets**

	<b>2024</b>	<b>2023</b>
	\$	\$
<i>Current assets</i>		
Prepayments	<u>109,980</u>	<u>51,909</u>
<i>Non-current assets</i>		
Security deposits	<u>119,100</u>	<u>82,886</u>
	<u>229,080</u>	<u>134,795</u>

**Note 11. Property, plant and equipment**

	<b>2024</b>	<b>2023</b>
	\$	\$
<i>Non-current assets</i>		
Plant and equipment - at cost	889,631	545,246
Less: Accumulated depreciation	<u>(366,840)</u>	<u>(160,140)</u>
	<u>522,791</u>	<u>385,106</u>

**Note 11. Property, plant and equipment (continued)**

*Reconciliations*

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

	\$
Balance at 1 July 2022	137,686
Additions	288,225
Depreciation expense	<u>(40,805)</u>
Balance at 30 June 2023	385,106
Additions	229,261
PPE acquired - Acquisition of TrialsWest (Refer Note 36)	27,481
Depreciation expense	<u>(119,057)</u>
Balance at 30 June 2024	<u><u>522,791</u></u>

**Note 12. Right-of-use assets**

	2024 \$	2023 \$
<i>Non-current assets</i>		
Land and buildings - right-of-use	778,105	406,880
Less: Accumulated depreciation	<u>(286,057)</u>	<u>(162,386)</u>
	<u><u>492,048</u></u>	<u><u>244,494</u></u>

The Group leases three premises.

*Reconciliations*

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

	Land and buildings \$
Balance at 1 July 2022	253,480
Additions	86,694
Depreciation expense	<u>(95,680)</u>
Balance at 30 June 2023	244,494
Additions	327,502
ROU acquired - Acquisition of TrialsWest (Refer Note 36)	43,721
Depreciation expense	<u>(123,669)</u>
Balance at 30 June 2024	<u><u>492,048</u></u>

For personal use only

Note 13. Intangibles

	2024 \$	2023 \$
<i>Non-current assets</i>		
Development - at cost	4,488,286	4,340,231
Goodwill	7,257,606	-
Less: Accumulated amortisation	<u>(1,882,102)</u>	<u>(1,626,882)</u>
	<u>9,863,790</u>	<u>2,713,349</u>

*Reconciliations*

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

	\$
Balance at 1 July 2022	2,865,005
Additions	179,678
Impairment of assets	(31,460)
Amortisation expense	<u>(299,874)</u>
Balance at 30 June 2023	2,713,349
Additions	148,054
Goodwill on acquisition of TrialsWest (Refer Note 36)	7,257,606
Amortisation expense	<u>(255,220)</u>
Balance at 30 June 2024	<u>9,863,790</u>

Development expenditure relates to costs incurred in developing MRI image analysis tools for the diagnosis and clinical management of human disease.

During the current financial year additional development has related to a new liver fat assessment tool, further refinement of FerriScan® and FerriSmart® and the next stage of development of an MRI based liver fibrosis tool.

The recoupment of development expenditure is dependent on the successful development and commercialisation or sale of the technology developed. The Directors are required to assess at each reporting date whether there is an indication that an asset may be impaired. If any such indication exists an estimate is made of the asset's recoverable amount. Impairment tests are also required for intangible assets not yet ready for use regardless of the existence of indicator of impairment. Where the asset's carrying value exceeds the estimated recoverable amount a provision for impairment is recognised.

As the Group has a number of intangible assets not yet ready for us, the Directors have conducted an impairment test as required by AASB136. In making this assessment the Directors had regard to the size of the liver fibrosis and liver fat markets, competing products, experience gained with the FerriScan® technology, the likely period over which these revenues are expected to be generated and the likelihood of any technological obsolescence.

The recoverable amount of development expenditure detailed above is determined based on value-in-use calculations.

Value-in-use is calculated based on the present value of cash flow projections over a five-year period.

**Note 13. Intangibles (continued)**

The following assumptions were used in the value-in-use calculations:

- Cashflows were forecast over a 5 year period with a terminal value applied.
- Growth rate was based on contractual obligations already in place and historical sales growth rates.
- Discount rate of 14.3%.
- Nil revenue growth rate applied to period beyond those covered by management forecast.
- Costs are calculated taking into account historical margins and trends as well as estimated weighted average inflation rates over the period, which are consistent with inflation rates appropriate to historic company rates.

On this basis, no impairment was necessary.

	2024 \$	2023 \$
Impairment Expense		
Ferriscan® - Image R2 platform conversion	-	17,541
Ferriscan® - Report writer	-	505
Iron blood marker study	-	13,414
	<u>-</u>	<u>31,460</u>

**Note 14. Trade and other payables**

	2024 \$	2023 \$
<i>Current liabilities</i>		
Trade payables (i)	301,765	145,316
Other payables	968,786	587,062
	<u>1,270,551</u>	<u>732,378</u>

- (i) Trade payables are non-interest bearing and are normally settled on 30-day terms. The carrying value of the trade payables is considered a reasonable approximation of fair value. Information regarding the effective interest rate and credit risk of current payables is set out in note 23.

**Note 15. Lease liabilities**

The Group leases three premises. The remaining term of the leases as of 30 June 2024 is 38, 14 and 6 months respectively.

	2024 \$	2023 \$
<i>Current liabilities</i>		
Lease liability	171,630	100,394
<i>Non-current liabilities</i>		
Lease liability	351,439	172,551
	<u>523,069</u>	<u>272,945</u>

Refer to note 22 for further information on financial instruments.

**Note 15. Lease liabilities (continued)**

Underlying assets serve as security for the related lease liabilities. A maturity analysis of future minimum lease payments is presented below:

	Lease payments due			Total \$
	1 year or less \$	Between 1 and 2 years \$	Between 2 and 5 years \$	
Lease payments	214,245	117,272	323,946	655,463
Interest	(42,613)	(31,542)	(58,239)	(132,394)
Net present values	<u>171,632</u>	<u>85,730</u>	<u>265,707</u>	<u>523,069</u>

**Note 16. Provisions**

	2024 \$	2023 \$
<i>Current liabilities</i>		
Provision for income tax	253,365	-
Long service leave	<u>119,776</u>	<u>31,414</u>
	<u>373,141</u>	<u>31,414</u>

**Note 17. Borrowings**

	2024 \$	2023 \$
<i>Current liabilities</i>		
Secured Financing Facility	320,000	-
<i>Non-Current liabilities</i>		
Secured Financing Facility	2,853,333	-

The finance facility has an expiry date of 31 March 2027 and an interest rate of BBSY + 2.5% per annum. The facility is secured over the whole of the assets of Resonance Health Limited and TrialsWest Pty Ltd.

**Note 18. Other liabilities**

	2024 \$	2023 \$
<i>Current liabilities</i>		
Unearned income	<u>11,240</u>	<u>11,188</u>

**Note 19. Issued capital**

	2024 Shares	2023 Shares	2024 \$	2023 \$
Ordinary shares - fully paid	<u>446,892,928</u>	<u>461,149,601</u>	<u>74,166,888</u>	<u>73,882,788</u>

**Note 19. Issued capital (continued)**

The Controlled Placement Agreement (CPA) that was entered into on 18 April 2019, was initially established with a limit of \$5m and the Company has utilised the CPA to raise a total of \$2.75m. On 30 June 2021 it was announced that the CPA limit was increased to \$7.75m and expiry date was extended to 31 July 2023. The Company had an available capacity of \$5m under the CPA. On 31 July 2023 the CPA expired and was not renewed.

	2024 Shares	2024 \$	2023 Shares	2023 \$
Issued Capital at the beginning of the financial year	461,149,601	73,882,788	461,149,601	73,882,788
Expiry of Controlled Placement Agreement	(20,000,000)	-	-	-
Performance Rights converted to shares on vesting	5,743,327	284,100	-	-
Issued Capital at the end of the financial year	<u>446,892,928</u>	<u>74,166,888</u>	<u>461,149,601</u>	<u>73,882,788</u>

*Capital risk management*

The Group's objectives when managing capital is to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital.

Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents.

In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

The Group would look to raise capital when an opportunity to invest in a business or company was seen as value adding relative to the current Company's share price at the time of the investment.

The capital risk management policy remains unchanged from 30 June 2023.

**Note 20. Reserves**

	2024 \$	2023 \$
Foreign currency reserve	(270,580)	(270,580)
Share-based payments reserve	2,907,725	2,364,805
	<u>2,637,145</u>	<u>2,094,225</u>

*Foreign currency reserve*

The reserve is used to recognise exchange differences arising from the translation of the financial statements of foreign operations to Australian dollars. It is also used to recognise gains and losses on hedges of the net investments in foreign operations.

*Share-based payments reserve*

The reserve is used to recognise the value of equity benefits provided to employees and Directors as part of their remuneration, and other parties as part of their compensation for services.

**Note 20. Reserves (continued)**

*Movements in reserves*

Movements in each class of reserve during the current and previous financial year are set out below:

	Foreign currency translation reserve \$	Share-based payments reserve \$	Total \$
Balance at 1 July 2022	(270,580)	2,340,374	2,069,794
Options expired	-	(23,894)	(23,894)
Performance rights vesting expense	-	48,325	48,325
Balance at 30 June 2023	(270,580)	2,364,805	2,094,225
Performance rights converted to shares	-	(284,100)	(284,100)
Performance rights vesting expense	-	827,020	827,020
Balance at 30 June 2024	<u>(270,580)</u>	<u>2,907,725</u>	<u>2,637,145</u>

**Note 21. Accumulated losses**

	2024 \$	2023 \$
Accumulated losses at the beginning of the financial year	(66,041,702)	(65,261,341)
Loss after income tax benefit for the year	169,303	(780,361)
Accumulated losses at the end of the financial year	<u>(65,872,399)</u>	<u>(66,041,702)</u>

**Note 22. Dividends**

There were no dividends paid, recommended or declared during the current or previous financial year.

**Note 23. Financial instruments**

***Financial risk management objectives***

The Group's activities expose it to a variety of financial risks: market risk (including foreign currency risk, price risk and interest rate risk), credit risk and liquidity risk. The Group's overall risk management approach focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the financial performance of the Group. The Group has not entered into or traded financial instruments, including derivative financial instruments such as forward foreign exchange contracts to hedge certain risk exposures.

Risk management is carried out by senior finance executives ('finance') under policies approved by the Board of Directors ('the Board'). These policies include identification and analysis of the risk exposure of the Group and appropriate procedures, controls and risk limits. Finance reports to the Board on a monthly basis.

***Market risk***

***Foreign currency risk***

The Group undertakes certain transactions denominated in foreign currency and is exposed to foreign currency risk through foreign exchange rate fluctuations.



**Note 23. Financial instruments (continued)**

Exchange rate exposures are managed by senior executives and the Board, the Group has not engaged in forward exchange contracts.

The carrying amount of the Group's foreign currency denominated financial assets and financial liabilities at the reporting date were as follows:

	Assets		Liabilities	
	2024 \$	2023 \$	2024 \$	2023 \$
US dollars (USD)	567,572	2,430,883	4,500	20,356
Euros (EUR)	82,878	564,709	-	-
Pound Sterling (GBP)	585,369	1,183,013	16,608	21,261
	<u>1,235,819</u>	<u>4,178,605</u>	<u>21,108</u>	<u>41,617</u>

*Foreign currency sensitivity analysis*

The Group is exposed to United States Dollar (USD), Great British Pound (GBP) and European Euro (EUR) currency fluctuations.

The following table illustrates the Group's sensitivity to a 10% increase and decrease in the Australian dollar against the relevant foreign currency. The sensitivity analysis includes only outstanding foreign currency denominated monetary items and adjusts their translation at the period end for a 10% change in foreign currency rates. A negative number indicates a decrease in profit and other equity where the Australian dollar strengthens against the respective currency. For a weakening of the Australian dollar against the respective currency there would be an equal and opposite impact on the profit and other equity and the balances below would be positive.

	2024 \$	2023 \$
Profit or loss impact:		
USD	(51,188)	(219,122)
EUR	(7,534)	(51,337)
GBP	(51,706)	(105,614)

*Price risk*

The Group is not exposed to any significant price risk.

*Interest rate risk*

All financial assets and financial liabilities are non-interest bearing except for cash and cash equivalent balances, the secured finance facility and lease liabilities. The following table details the Group's expected maturities for cash and cash equivalent financial assets.

For personal use only

**Note 23. Financial instruments (continued)**

Cash and cash equivalent financial assets:

	2024		2023	
	Weighted average interest rate %	Balance \$	Weighted average interest rate %	Balance \$
Less than one month	0.50%	3,420,788	-	5,324,561
One to three months	3.02%	3,434,032	4.10%	1,037,061
		<u>6,854,820</u>		<u>6,361,622</u>

The Group is exposed to fluctuations in interest rates as it has deposited monies at floating interest rates. The impact of a 100bp change in interest rates will not have a material impact on the result for the year.

**Credit risk**

Credit risk is the risk that a counter party will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Group is exposed to credit risk from its operating activities (primarily from customer receivables) and from its financing activities, including deposits with banks, foreign exchange transactions and other financial instruments.

Outstanding customer receivables are regularly monitored and any credit concerns highlighted to senior management. At 30 June 2024, the Group had two customers that accounted for 42% of all trade receivables (2023: 9%). Refer note 9 for further details.

The maximum exposure to credit risk, excluding the value of any collateral or other security at balance date in relation to each class of recognised financial assets is the carrying amount, net of any allowance for impairment recorded in the financial statements. The Group does not hold any collateral as security for any trade receivable.

**Liquidity risk**

Ultimate responsibility for liquidity risk management rests with the Board of Directors, who have built an appropriate liquidity risk management framework for the management of the Group's short, medium and long-term funding and liquidity management requirements. The Group manages liquidity risk by maintaining adequate reserves by continually monitoring forecast and actual cash flows and matching the maturity profiles of financial assets and liabilities.

For personal use only

**Note 23. Financial instruments (continued)**

*Remaining contractual maturities*

The following tables detail the Group's remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore these totals may differ from their carrying amount in the statement of financial position.

	Weighted average interest rate	1 year or less	Between 1 and 2 years	Between 2 and 5 years	Over 5 years	Remaining contractual maturities
	%	\$	\$	\$	\$	\$
<b>2024</b>						
<b>Non-derivatives</b>						
<i>Non-interest bearing</i>						
Trade payables	-	301,765	-	-	-	301,765
Other payables	-	968,786	-	-	-	968,786
Deferred Consideration Payable	-	4,000,000	-	-	-	4,000,000
<i>Interest-bearing - fixed rate</i>						
Lease liability	8.99%	171,632	85,730	265,708	-	523,070
<i>Interest-bearing – floating rate</i>						
Secured financing facility	7.30%	320,000	320,000	2,533,333	-	3,173,333
Total non-derivatives		<u>5,762,183</u>	<u>405,730</u>	<u>2,799,041</u>	<u>-</u>	<u>8,966,954</u>
	Weighted average interest rate	1 year or less	Between 1 and 2 years	Between 2 and 5 years	Over 5 years	Remaining contractual maturities
	%	\$	\$	\$	\$	\$
<b>2023</b>						
<b>Non-derivatives</b>						
<i>Non-interest bearing</i>						
Trade payables	-	145,316	-	-	-	145,316
Other payables	-	587,062	-	-	-	587,062
<i>Interest-bearing – fixed rate</i>						
Lease liability	5.06%	<u>100,394</u>	<u>143,463</u>	<u>29,088</u>	<u>-</u>	<u>272,945</u>
Total non-derivatives		<u>832,772</u>	<u>143,463</u>	<u>29,088</u>	<u>-</u>	<u>1,005,323</u>

The cash flows in the maturity analysis above are not expected to occur significantly earlier than contractually disclosed above.

**Fair value of financial instruments**

Unless otherwise stated, the carrying amounts of financial instruments reflect their fair value.

For personal use only

**Note 24. Key management personnel disclosures**

*Directors*

The following persons were Directors of Resonance Health Limited during the financial year:

Dr Martin Blake  
Mr Mitchell Wells  
Mr Simon Panton  
Dr Travis Baroni  
Mr Aaron Brinkworth

*Other key management personnel*

The following persons also had the authority and responsibility for planning, directing and controlling the major activities of the Group, directly or indirectly, during the financial year:

Mr Andrew Harrison Chief Executive Officer  
Mr Benjamin Carruthers Chief Financial Officer

*Compensation*

The aggregate compensation made to Directors and other members of key management personnel of the Group is set out below:

	2024 \$	2023 \$
Short-term employee benefits	957,950	606,302
Non-monetary short term benefit	18,912	-
Post-employment benefits	57,546	62,619
Share-based payments	318,690	48,325
	<u>1,353,098</u>	<u>717,246</u>

**Note 25. Remuneration of auditors**

During the financial year the following fees were paid or payable for services provided by HLB Mann Judd, the auditor of the Company:

	2024 \$	2023 \$
<i>Audit services -- HLB Mann Judd</i>		
Audit or review of the financial statements	<u>61,662</u>	<u>74,901</u>
<i>Other services – HLB Mann Judd</i>		
Preparation of the tax return	<u>10,350</u>	<u>9,500</u>
	<u>72,012</u>	<u>84,401</u>

**Note 26. Contingent assets**

The Group has no contingent assets as at 30 June 2024 (2023: \$nil).

For personal use only

**Note 27. Contingent liabilities**

On 10 September 2020 the Company announced that they had entered into a licence agreement with the Telethon Kids Institute ("Telethon Kids") and the Erasmus University Medical Centre for the use of computer tomography ("PRAGMA-CF Data") datasets that will be used by the Company in the potential development of a new artificial intelligence ("AI") algorithm for the automated assessment of lung disease progression in patients with cystic fibrosis.

Under the agreement a 10% net royalty on all sales of the analysis performed by the Device will be payable by the Group and a further 297,620 ordinary shares will be issued on submission of the medical device dossier.

During the year the likelihood of any outflow to the group from this transaction has been re-assessed as being sufficiently remote to no longer consider this as being a contingent liability.

**Note 28. Commitments**

The Group has no operating or capital commitments.

**Note 29. Related party transactions**

*Parent entity*

Resonance Health Limited is the parent entity.

*Subsidiaries*

Interests in subsidiaries are set out in note 31.

*Key management personnel*

Disclosures relating to key management personnel are set out in note 24 and the remuneration report included in the Directors' report.

*Transactions with related parties*

The following transactions occurred with related parties:

	2024 \$	2023 \$
Sale of goods and services:		
Services provided to Perth Radiological Clinic *	1,915	2,426
Payment for goods and services:		
Services provided by Perth Radiological Clinic *	545	60
Payment for goods and services:		
Services provided by SynGenis Pty Ltd**	12,404	-

\* Dr Martin Blake is a shareholder, Director and consulting Radiologist of Perth Radiological Clinics.

\*\* Dr Martin Blake is a board member of SynGenis Pty Ltd

For personal use only

**Note 29. Related party transactions (continued)**

*Receivable from and payable to related parties*

The following balances are outstanding at the reporting date in relation to transactions with related parties:

	2024 \$	2023 \$
Current receivables:		
Trade receivables from Perth Radiological Clinic	307	593
Current payables:		
Trade payables to SynGenis Pty Ltd	8,026	-

*Loans to/from related parties*

There were no loans to or from related parties at the current and previous reporting date.

*Terms and conditions*

All transactions were made on normal commercial terms and conditions and at market rates.

**Note 30. Parent entity information**

Set out below is the supplementary information about the parent entity.

*Statement of profit or loss and other comprehensive income*

	Parent	
	2024 \$	2023 \$
Loss after income tax	(1,465,736)	(430,226)
Total comprehensive income	(1,465,736)	(430,226)

*Statement of financial position*

	Parent	
	2024 \$	2023 \$
Total current assets	4,102,418	2,185,987
Total assets	8,959,100	4,050,405
Total current liabilities	(399,470)	81,644
Total liabilities	(6,051,279)	(503,868)
Equity		
Issued capital	74,166,888	73,882,788
Share-based payments reserve	2,907,725	2,364,805
Accumulated losses	(74,166,792)	(72,701,056)
Total equity	2,907,821	3,546,537

**Note 31. Interests in subsidiaries**

The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 2:

Name	Principal place of business / Country of incorporation	Ownership interest	
		2024 %	2023 %
Resonance Health Analysis Services Pty Ltd	Australia	100%	100%
CRO Services Pty Ltd*	Australia	100%	100%
Resonance Health Laboratory Services Pty Ltd**	Australia	100%	100%
Resonance USA Inc	USA	100%	100%
TrialsWest Pty Ltd	Australia	100%	-

\* previously WA Private Health Care Services Pty Ltd

\*\* previously IVB Holdings Pty Ltd

**Note 32. Events after the reporting period**

No matter or circumstance has arisen since 30 June 2024 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

**Note 33. Cash flow information**

*Reconciliation of loss after income tax to net cash used in operating activities*

	2024 \$	2023 \$
Loss after income tax benefit for the year	169,303	(780,361)
Adjustments for:		
Depreciation and amortisation	497,946	436,359
Impairment of intangibles	-	31,460
Interest expense	19,680	-
Share-based payments	827,020	24,431
Foreign exchange differences	(38,390)	(285,356)
Change in operating assets and liabilities:		
Decrease/(increase) in trade and other receivables	(450,445)	361,170
Decrease/(increase) in prepayments	(58,069)	7,645
Increase in trade and other payables	331,787	35,106
Increase/(decrease) in employee benefits	88,362	23,741
Decrease in other operating liabilities	54	(11,223)
Net cash used in operating activities	<u>1,387,248</u>	<u>(157,028)</u>

**Note 33. Cash flow information (continued)**

*Changes in liabilities arising from financing activities*

	<b>Borrowings</b>	<b>Lease liabilities</b>
	<b>\$</b>	<b>\$</b>
Balance at 1 July 2022	-	268,221
Net cash used in financing activities	-	(81,967)
Leases entered	-	86,692
	<hr/>	<hr/>
Balance at 30 June 2023	-	272,946
Net cash used in financing activities	3,173,333	(127,922)
Lease Interest	-	19,680
Lease Payables	-	(12,859)
Leases entered	-	371,225
	<hr/>	<hr/>
Balance at 30 June 2024	<u>3,173,333</u>	<u>523,068</u>

**Note 34. Earnings per share**

	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
Profit/(Loss) after income tax attributable to the owners of Resonance Health Limited	<u>169,303</u>	<u>(780,361)</u>
	<b>Number</b>	<b>Number</b>
Weighted average number of ordinary shares used in calculating basic earnings per share	<u>456,064,369</u>	<u>461,149,601</u>
Weighted average number of ordinary shares used in calculating diluted earnings per share	<u>468,471,042</u>	<u>461,149,601</u>
	<b>Cents</b>	<b>Cents</b>
Basic profit/(loss) per share	0.04	(0.17)
Diluted profit/(loss) per share	0.04	(0.17)

**Note 35. Share-based payments**

The Company has an Employee Incentive Plan for key staff members and consultants of the Company.

For personal use only



**Note 35. Share-based payments (continued)**

**Options**

Set out below are summaries of options granted under the plan:

	Number of options 2024	Weighted average exercise price 2024	Number of options 2023	Weighted average exercise price 2023
Outstanding at the beginning of the financial year	-	-	12,200,000	\$0.175
Expired	-	-	(12,200,000)	\$0.175
Outstanding at the end of the financial year	-	-	-	\$0.000
Exercisable at the end of the financial year	-	-	-	\$0.000

10,000,000 options are due to an employee of the Company as part of their employee agreement which are yet to be issued, with an exercise price of \$0.095 and an expiry date of 30 June 2029. The fair value of these options is \$0.029 per option. These options are subject to vesting conditions which aren't considered probable to be met at year end. As a result no expense has been booked for these options.

**Performance Rights**

	Number of performance rights 2024
On issue at the beginning of the financial year	-
Issued	21,938,709
Converted to Shares	(5,743,327)
Cancelled	(3,788,709)
On issue at the end of the financial year	12,406,673

1,830,000 Performance rights were issued to Mitchell Wells on 11 October 2023, in accordance with a resolution of the Company's shareholders at it's 2022 Annual General Meeting (**AGM**) with the following vesting conditions:

Tranche	Number granted	Vesting Date
A	610,000	1 October 2023
B	610,000	1 October 2024
C	610,000	1 October 2025
	1,830,000	

The performance rights were issued for nil cash consideration and are convertible into fully paid ordinary shares in the capital of the Company, upon vesting.

During the year, Tranche A of the performance rights vested and were converted to shares.

These performance rights were valued, using a valuation methodology based on the guidelines set out in AASB 2 *Share-based Payment*.

For personal use only

**Note 35. Share-based payments (continued)**

For the performance rights granted during the current financial year to Mitchell Wells, the valuation model inputs used to determine the fair value at the grant date, are as follows:

Assumptions:	Tranche A	Tranche B	Tranche C
Number of performance rights	610,000	610,000	610,000
Valuation date	24 November 2022	24 November 2022	24 November 2022
Share price on valuation date	\$0.064	\$0.064	\$0.064
<b>Indicative value per performance right</b>	<b>\$0.064</b>	<b>\$0.064</b>	<b>\$0.064</b>
- Mr Mitchell Wells	\$39,040	\$39,040	\$39,040

The value of the performance rights are being expensed over the deemed life of the Rights, from shareholder approval. During the period, \$46,382 was recognised as an expense in relation to the rights.

20,108,709 Performance rights were issued to Employees of the Company on 11 October 2023, with the following vesting conditions:

Tranche	Number granted	Vesting Date
A	6,702,907	1 year anniversary of employment
B	6,702,901	2 year anniversary of employment
C	6,702,901	3 year anniversary of employment
	20,108,709	

The performance rights were issued for nil cash consideration and are convertible into fully paid ordinary shares in the capital of the Company, upon vesting.

During the year, 5,133,336 Tranche A performance rights vested and were converted to shares on meeting of the service condition. A further 3,788,709 performance rights were cancelled prior to vesting.

These performance rights were valued, using a valuation methodology based on the guidelines set out in AASB 2 *Share-based Payment*.

For the performance rights granted during the current financial year to Employees, the valuation model inputs used to determine the fair value at the grant date, are as follows:

Assumptions:	Tranche A	Tranche B	Tranche C
Number of performance rights	6,702,907	6,702,901	6,702,901
Valuation date	Between 27 June 2023 and 11 October 2023	Between 27 June 2023 and 11 October 2023	Between 27 June 2023 and 11 October 2023
Average share price on valuation date	\$0.052	\$0.52	\$0.052
<b>Indicative value per performance right</b>	<b>\$0.052</b>	<b>\$0.052</b>	<b>\$0.052</b>
- Employees	\$357,603	\$357,603	\$357,603

The value of the performance rights are being expensed over the deemed life of the Rights, from shareholder approval. During the period, \$780,638 was recognised as an expense in relation to the rights.

**Note 35. Share-based payments (continued)**

Reconciliation of share based payments expense:

	2024 \$	2023 \$
Options to staff and consultants	-	(23,894)
Vesting of performance rights	827,020	48,325
	<u>827,020</u>	<u>24,431</u>

**Note 36. Acquisition of TrialsWest**

On 31 May 2024 the Company completed the acquisition of TrialsWest Pty Ltd (**TrialsWest**). Under the terms of the agreement the Company paid \$4 million upfront cash consideration. A further \$4 million may be payable to the TrialsWest vendors pursuant to an earnout arrangement – subject to EBITDA performance targets being achieved during FY24 – FY26.

The fair value of TrialsWest’s net assets acquired and the resulting goodwill and tax balances have been measured provisionally. If new information obtained within one year of the date of acquisition about facts and circumstances that existed at the date of acquisition identifies adjustments to the above amounts, or any additional provisions that existed at the date of acquisition, then the requirements of the Australian Accounting Standards permits the acquisition values to be revised. This acknowledges the time required to gain access to and consolidate information for both entities and to make certain valuations as at the acquisition date. Any changes to these provisional values will be reported within the next reporting period. The amounts in the table on the following page have been measured on a provisional basis.

A summary of the acquisition is as follows:

	\$
Cash consideration	4,000,000
Deferred consideration	4,000,000
Total Consideration	<u>8,000,000</u>
Assets acquired and liabilities assumed at fair value	
Cash and cash equivalents	435,677
Trade and other receivables	726,127
Plant and equipment	27,481
Right of use assets	43,721
Trade and other payables	(177,906)
Provisions	(268,985)
Lease Liability	<u>(43,721)</u>
Provisional fair value of identifiable net assets acquired	<u>742,394</u>
Provisional goodwill arising on acquisition	<u><u>7,257,606</u></u>

For personal use only

**Note 36. Acquisition of TrialsWest (continued)**

As at 30 June 2024, the goodwill is provisional on completing the further identification of separately identifiable intangible assets.

From the date of acquisition (31 May 2024), TrialsWest contributed \$204,771 of consolidated net income and a net profit before tax of \$97,869 to the Group. If the acquisition had taken place at the beginning of the period (i.e., 1 July 2023), TrialsWest would have contributed consolidated net income of \$2,348,143 and consolidated net profit before tax of \$1,025,769.

The directors have made an assessment of the likelihood of the deferred consideration being payable at the date of acquisition. As a result of this assessment the full \$4,000,000 deferred consideration has been recorded as a liability.

For personal use only

**Resonance Health Limited**  
**Consolidated entity disclosure statement**  
**As at 30 June 2024**

<b>Entity Name</b>	<b>Entity Type</b>	<b>Place Formed/ Country of Incorporation</b>	<b>Ownership interest %</b>	<b>Tax residency</b>
Resonance Health Limited	Body Corporate	Australia	100%	Australia
Resonance Health Analysis Services Pty Ltd	Body Corporate	Australia	100%	Australia
CRO Services Pty Ltd	Body Corporate	Australia	100%	Australia
Resonance Health Laboratory Services Pty Ltd	Body Corporate	Australia	100%	Australia
Resonance USA Inc	Body Corporate	USA	100%	USA, Australia
TrialsWest Pty Ltd	Body Corporate	Australia	100%	Australia

For personal use only

**Resonance Health Limited**  
**Directors' declaration**  
**30 June 2024**

In the Directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, the Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes comply with International Financial Reporting Standards as issued by the International Accounting Standards Board as described in note 2 to the financial statements;
- the attached financial statements and notes give a true and fair view of the Group's financial position as at 30 June 2024 and of its performance for the financial year ended on that date; and
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.
- the information disclosed in the attached consolidated entity disclosure statement is true and correct.

The Directors have been given the declarations required by section 295A of the Corporations Act 2001.

Signed in accordance with a resolution of Directors made pursuant to section 295(5)(a) of the Corporations Act 2001.

On behalf of the Directors



---

Dr Martin Blake  
Chair

29 August 2024  
Perth, Western Australia

For personal use only

## INDEPENDENT AUDITOR'S REPORT

To the Members of Resonance Health Limited

### Report on the Audit of the Financial Report

#### *Opinion*

We have audited the financial report of Resonance Health Limited ("the Company") and its controlled entities ("the Group"), which comprises the consolidated statement of financial position as at 30 June 2024, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, notes to the financial statements, including material accounting policy information, the consolidated entity disclosure statement and the directors' declaration.

In our opinion, the accompanying financial report of the Group is in accordance with the *Corporations Act 2001*, including:

- (a) giving a true and fair view of the Group's financial position as at 30 June 2024 and of its financial performance for the year then ended; and
- (b) complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

#### *Basis for Opinion*

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* ("the Code") that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### *Key Audit Matters*

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined the matters described below to be the key audit matters to be communicated in our report.

**hlb.com.au**

**HLB Mann Judd ABN 22 193 232 714**

A Western Australian Partnership

Level 4, 130 Stirling Street, Perth WA 6000 / PO Box 8124 Perth BC WA 6849

T: +61 (0)8 9227 7500 E: mailbox@hlbwa.com.au

Liability limited by a scheme approved under Professional Standards Legislation.

HLB Mann Judd is a member of HLB International, the global advisory and accounting network.

Key Audit Matter	How our audit addressed the key audit matter
<p><b>Intangible assets</b> Refer to Note 13</p> <p>As at 30 June 2024, the Group has intangible assets, comprising of development assets and goodwill arising from the acquisition of TrialsWest Pty Ltd.</p> <p>Under AASB 136 Impairment of Assets, intangible assets not yet available for use are subject to an annual impairment test and other intangible assets are subject to an impairment test should indicators of impairment arise.</p> <p>We considered this to be a key audit matter as it involves subjectivity and judgement, it is material to the users' understanding of the financial statements as a whole and it required significant auditor attention and communication with those charged with governance.</p>	<p>Our procedures included but were not limited to:</p> <ul style="list-style-type: none"> <li>• We critically evaluated management's methodology in the value-in-use model and the basis for key assumptions;</li> <li>• We performed sensitivity analyses around the key inputs used in the cash flow forecasts that either individually or collectively would be required for assets to be impaired and considered the likelihood of such a movement in those key assumptions arising;</li> <li>• We reviewed the key inputs management used to determine the necessary impairment;</li> <li>• We considered whether the assets comprising the cash-generating unit had been correctly allocated;</li> <li>• We ensured that balances capitalised met the recognition criteria under AASB 138 Intangible Assets; and</li> <li>• Assessed the appropriateness of the disclosures included in the relevant notes to the financial report.</li> </ul>
<p><b>Revenue Recognition</b> Refer to Note 5</p> <p>The Company recognises revenue from commercial revenue, clinical trials revenue and other studies recorded either at a point in time or over time based upon the relevant performance obligation(s).</p> <p>We focused on this area as a key audit matter due to it being material to the users' understanding of the financial statements and it requiring significant auditor attention and communication with those charged with governance.</p>	<p>Our audit procedures included but were not limited to the following:</p> <ul style="list-style-type: none"> <li>• We evaluated management's processes and key controls regarding accounting for the Group's revenue;</li> <li>• We ensured that recognition of revenue was consistent with the requirements of AASB 15;</li> <li>• We performed substantive testing over revenue;</li> <li>• We ensured revenue was correctly recorded based upon the relevant performance obligation(s) and was recorded in the correct period; and</li> <li>• We ensured adequate disclosure in the financial report.</li> </ul>



---

### Acquisition of TrialWest Pty Ltd

Refer to Note 36

The Company completed the acquisition of TrialsWest Pty Ltd (TrialsWest) on 31 May 2024.

The fair value of TrialsWest's net assets acquired and the resulting goodwill have been measured provisionally. As at 30 June 2024, the goodwill is provisional on completing the further identification of separately identifiable intangible assets and valuation of the deferred consideration.

We focused on this area as a key audit matter as accounting for these transactions is a complex and judgemental exercise, requiring management to determine the fair value of acquired assets and liabilities, in particular determining the allocation of purchase consideration to goodwill and separately identifiable intangible assets.

Our audit procedures included but were not limited to the following:

- We read the acquisition agreement to understand their key terms and conditions;
- We agreed the fair value of the consideration to supporting information;
- We assessed that the acquisition met the criteria for a business combination;
- We obtained audit evidence that the acquisition-date assets and liabilities of each business were fairly stated;
- We considered the allocation of the excess of the consideration paid over the identifiable net assets acquired to goodwill and other intangible assets, in accordance with AASB 3; and
- We assessed the adequacy of the Group's disclosures in the financial report with respect to the acquisitions.

---

### Other Information

The directors are responsible for the other information. The other information comprises the information included in the Group's annual report for the year ended 30 June 2024, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report, or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### Responsibilities of the Directors for the Financial Report

The directors of the Company are responsible for the preparation of:

- (a) the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001*; and
- (b) the consolidated entity disclosure statement that is true and correct in accordance with the *Corporations Act 2001*, and

for such internal control as the directors determine is necessary to enable the preparation of:

- (a) the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and
- (b) the consolidated entity disclosure statement that is true and correct and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

#### *Auditor's Responsibilities for the Audit of the Financial Report*

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the financial report of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

## **REPORT ON THE REMUNERATION REPORT**

### *Opinion on the Remuneration Report*

We have audited the Remuneration Report included within the Directors' Report for the year ended 30 June 2024.

In our opinion, the Remuneration Report of Resonance Health Limited for the year ended 30 June 2024 complies with Section 300A of the *Corporations Act 2001*.

### *Responsibilities*

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with Section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.



**HLB Mann Judd**  
**Chartered Accountants**

**Perth, Western Australia**  
**29 August 2024**



**N G Neill**  
**Partner**

For personal use only

**Resonance Health Limited**  
**Shareholder information**  
**30 June 2024**

The following additional information is disclosed in accordance with section 4.10 of the Australia Securities Exchange Listing Rules in respect of a listed public company.

**Corporate Governance**

In recognising the need for the highest standards of corporate behaviour and accountability, the Directors of Resonance Health Limited support and adhere to the principles of corporate governance. The Company's Corporate Governance Statement is contained on the Company's web site located here:  
<http://www.resonancehealth.com>

The shareholder information set out below was applicable as at 25 August 2024.

**Distribution of equitable securities**

Analysis of number of equitable security holders by size of holding:

	Ordinary shares		
	Number of holders	Number of	% of total shares issued
1 to 1,000	120	18,326	0.00
1,001 to 5,000	191	698,544	0.16
5,001 to 10,000	202	1,622,923	0.36
10,001 to 100,000	876	36,915,657	8.26
100,001 and over	420	407,637,478	91.22
	<u>1,809</u>	<u>446,892,928</u>	<u>100.00</u>
Holding less than a marketable parcel	<u>426</u>	<u>1,485,701</u>	<u>0.33</u>

For personal use only

### Equity security holders

*Twenty largest quoted equity security holders*

The names of the twenty largest security holders of quoted equity securities are listed below:

	Ordinary shares	% of total
	Number held	shares issued
SOUTHAM INVESTMENTS 2003 PTY LTD <WARWICKSHIRE INVESTMENT A/C>	74,300,000	16.63
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	49,401,078	11.05
MR PAUL JOHN VAN DYK	9,250,031	2.07
MR ANDREW DUNCAN HARRISON & MRS KATRINA ELLEN HARRISON <HARRISON SUPER FUND A/C>	8,000,000	1.79
MR WILLIAM MURRAY THOMPSON	6,658,660	1.49
MS JADE LOUISE THOMPSON	6,512,759	1.46
MR HARISH GARG	6,500,000	1.45
MR BRUCE ALAN STEVENSON	6,400,000	1.43
MR PAUL ANDREW FITZMAURICE & MRS TANIA MARIE FITZMAURICE <FITZMAURICE FAMILY S/F A/C>	5,250,000	1.17
MARCOLONGO NOMINEES PTY LTD <MARCOLONGO FAMILY A/C>	5,186,200	1.16
MR HELMUT ROCKER	5,000,000	1.12
MR THOMAS PSARAKIS	4,434,777	0.99
MR EVAN GEORGE CROSS & MRS DONNA SHARON CROSS <DEC SUPERANNUATION FUND A/C>	4,000,000	0.90
DR MARTIN PETER BLAKE	3,798,590	0.85
DR RUSSELL KAY HANCOCK	3,782,704	0.85
THE UNIVERSITY OF WESTERN AUSTRALIA	3,478,750	0.78
MORGAN STANLEY AUSTRALIA SECURITIES (NOMINEE) PTY LIMITED (NO 1 ACCOUNT)	3,305,746	0.74
NEWECOMY COM AU NOMINEES PTY LIMITED (900 ACCOUNT)	3,197,656	0.72
CORNUCOPIA ASSETS PTY LTD <CORNUCOPIA SUPER FUND A/C>	3,140,000	0.70
MR ROBERT FRANCIS PANTON	2,800,000	0.63
	<u>214,396,951</u>	<u>47.97</u>

### Substantial holders

Substantial holders in the Company are set out below:

	Ordinary shares	% of total
	Number held	shares issued
SOUTHAM INVESTMENTS 2003 PTY LTD <WARWICKSHIRE INVESTMENT A/C>	74,300,000	16.63
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	49,401,078	11.05

For personal use only

**Voting rights**

The voting rights attached to ordinary shares are set out below:

*Ordinary shares*

On a poll any member voting in advance by proxy or present at a meeting in person or by proxy shall have one vote per share.

For personal use only